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ABSTRACT 
Cell sheet engineering is a novel and effective means of forming tissue substitutes in 
regenerative medicine. This technology allows for the manufacturing of cell sheets for 
either direct transplantation or the assembly of three-dimensionally organized tissue-
mimicking structures. In the last decade, cell sheet engineering emerged as a promising 
alternative to injected cell delivery and biomaterial vehicles. Cell sheets manufactured 
on thermosensitive polymer coatings are already successfully employed in clinical 
applications such as human corneal reconstruction and treatment of human myocardial 
dysfunction.  
The main goal of my thesis was to develop an alternative, electrochemically responsive 
surface coating for the site-specific release of cell sheets by applying of micro-electrical 
currents. In context of my work, polyelectrolyte multilayer (PEM)-based platforms 
should be used for the synthesis of cell sheets composed of human stem / progenitor 
and end-differentiated cells. 
In the first part of my thesis, I determined the critical parameters for the isolation and 
long-term cultivation of human term placenta-derived mesenchymal stem cells (PD-
MSCs). My results revealed that the isolated cells were of maternal origin and possessed 
very high proliferation and very low mortality rates up to passage twenty. The 
phenotypic profile of PD-MSC-isolates fulfilled the recently defined minimal criteria for 
the determination of mesenchymal stem cells (MSCs) and remained constant 
throughout continuous sub-confluent culture. The plasticity of PD-MSCs allowed their 
differentiation into adipogenic, chondrogenic, and osteogenic lineages as well as 
endothelium. 
In the second part of my thesis, I designed and optimized a PEM-based platform for the 
growth and intact peeling of cell sheets generated from different human cell types. 
Therefore, I established PEM substrates of a constant thickness with variations in 
rigidity. As a preliminary experiment, I used the assembly composed from nine layer-
pairs of positively-charged poly-L-lysine (PLL) and negatively-charged hyaluronic acid 
(HA). The use of such polymers allowed for the construction of soft coatings and has 
been previously described as an attractive system for culturing different cell types. 
Moreover, the coating stiffness was adjusted by modulating the heterobifunctional 
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crosslinkers present. For the assembly of stiff coatings, I used a film comprised of 
positively-charged poly-(allylamine)-hydrochloride (PAH) and negatively-charged poly-
(styrene)-sulfonate (PSS). The potential of such coatings in cell sheet formation was 
previously demonstrated by endothelial cell cultivation. I demonstrated that the 
stiffness of the PEM substrate plays a critical role in the adhesion, spreading, and 
growth of human cells. Although the soft substrate supported the adhesion of the 
control murine muscle cell line C2C12, it only provided a minimal support for the 
adhesion of human cell types such as placenta-derived MSCs (PD-MSCs), adipose 
tissue-derived MSCs (AT-MSCs), human muscle cells (HMCs), human umbilical cord 
endothelial cells (HUVECs), and human late outgrowth endothelial cells (OECs). In 
contrast, the semi-stiff and stiff substrates were deemed suitable in culturing all of the 
tested human cell types and allowed for the complete mesodermal differentiation of 
stem cell sheets generated from AT-MSCs and PD-MSCs. 
In the final part of my thesis, I established the optimal conditions for the generation and 
detachment of PD-MSC sheets. In order to find a PEM architecture that minimally 
affected the cell sheet growth, I decided to utilize stiff (PAH/PSS) coatings. Such 
coatings supported the successful formation of PD-MSC sheets without any chemical 
modification. They also allowed for cell sheet detachment mediated either 
electrochemically by applying the micro-electrical current about 1.8 mV or by decreasing 
the environmental pH to 4. The viable PD-MSC sheets that detached from the 
(PAH/PSS) platform were able to adhere on the fresh TCPS substrates and could be 
successfully differentiated towards adipogenesis and osteogenesis. 
In summary, my thesis explored and implemented a PEM-based platform as substrates 
for cell sheet engineering and differentiation. Comparable with costly classical 
thermosensitive platforms, economically priced PEM based platforms allowed 
formation of cell sheets from different human stem / progenitor and adult cell types 
during a very short time period. Moreover, charge and pH-mediated peeling of cell 
sheets supported by PEM platforms are not only faster, but easier to automatize than 
thermosensitive platforms as well. My results lead me to believe that PEM based 
platforms indeed have potential as substrates for cell sheet engineering. They can be 
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used for manufacturing single stem cell sheets geared for direct transplantation or for 
the generation of tissue-like structures destined for drug screening applications. 
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ZUSAMMENFASSUNG 
Die Engineering der Zellschichten oder „Cell Sheet Engineering“ hat sich zu einer 
modernen und effektiven Technik für die regenerative Medizin entwickelt. Diese 
Technologie ermöglicht die Herstellung von Zellschichten für die direkte 
Transplantation oder den Zusammenbau von dreidimensional organisierten, 
gewebeähnlichen Strukturen. Im letzten Jahrzehnt wurde „Cell Sheet Engineering“ eine 
vielversprechende Alternative zur Verabreichung von Zellen durch Injektion oder 
mittels Biomaterialien. Zellschichten, welche auf wärmeempfindlichen 
Polymerbeschichtungen hergestellt werden, können bereits erfolgreich in klinischen 
Anwendungen wie beim Wiederaufbau von Hornhaut oder der Behandlung von 
menschlicher Myokarddysfunktion eingesetzt worden. 
Das Hauptziel meiner Arbeit war die Entwicklung einer alternativen, auf 
elektrochemische Signale reagierenden Oberflächenbeschichtung, welche die 
ortsspezifische Freisetzung von Zellschichten durch Anlegen einer Mikro-elektrischer 
Ladung erlaubt. Im Rahmen meiner Arbeit wurde eine Polyelektrolyt-Multischicht 
(PEM)-basierte Plattform verwendet, um Zellenschichten aus menschlichen 
Stammzellen und enddifferenzierten Zellen herzustellen. 
Im ersten Teil meiner Dissertation habe ich kritische Parameter für die Isolation und 
langfristige Kultivierung von mesenchymalen Stammzellen aus humaner Plazenta (PD-
MSCs) bestimmt. Meine Ergebnisse zeigen, dass die isolierten Zellen mütterlichen 
Ursprungs sind und in den ersten zwanzig Passagen eine sehr hohe Proliferationsrate 
und gleichzeitig eine sehr niedrige Sterblichkeitsrate aufweisen. Die isolierten PD-MSC 
erfüllen mit ihrem phänotypischen Profil die kürzlich definierten Minimalkriterien für 
die Bestimmung von mesenchymalen Stammzellen (MSCs) und bleiben während 
kontinuierlicher sub-konfluenter Kultur phänotypisch stabil. Die PD-MSCs weisen eine 
Plastizität auf, die deren Differenzierung in Richtung Adipogenese, Chondrogenese und 
Osteogenese sowie Endothelium erlaubt. 
Im zweiten Teil meiner Dissertation habe ich eine optimierte PEM-basierte Plattform 
zur Herstellung von intakten Zellschichten entworfen und dahingehend optimiert, dass 
aus unterschiedlichen menschlichen Zelltypen Zellschichten erzeugt und von der 
Oberfläche abgelöst werden können. Dazu habe ich PEM Substrate mit konstanter Dicke 
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und variabler Steifigkeit hergestellt. Als Anfangsbedingung habe ich neun 
Doppelschichten aus positiv geladenen Poly-L-Lysin (PLL) und negativ geladenen 
Hyaluronsäure (HA) gebildet. Eine solche Zusammensetzung von Polymeren erlaubt es, 
weiche Beschichtungen zu erzeugen welche schon als attraktives System für die Kultur 
der verschiedenen Zelltypen beschrieben wurden. Zudem können die mechanischen 
Eigenschaften solcher Schichten durch Versteifung mit einem kreuzvernetzenden 
Reagenz geändert werden, so dass halbsteife Substrate entstehen. Für die Herstellung 
von steifen Beschichtungen habe ich positiv geladene Poly-(Allylamin)-Hydrochlorid 
(PAH) und negativ geladene Poly-(Styrol)-sulfonat (PSS) verwendet. Dass solche 
Beschichtungen für die Bildung von Zellschichten geeignet sind wurde zuvor durch die 
Kultur von Endothelzellen gezeigt. Ich konnte darüber hinaus zeigen, dass die Steifigkeit 
der PEM Beschichtung eine entscheidende Rolle für die Adhäsion, die Ausbreitung und 
das Wachstum von menschlichen Zellen spielt. Obwohl der weiche Untergrund die 
Anhaftung der Maus Muskel-Zelllinie C2C12 unterstützt, konnte unter diesen 
Bedingungen nur eine minimale Haftung von menschlichen Zelltypen wie PD-MSCs, 
aus Fettgewebe gewonnenen MSCs (AT-MSCs), menschlichen Muskelzellen (HMC), 
menschliche Nabelschnur Endothelzellen (HUVECs) und menschliche Endothelzellen 
aus Nabelschnurblut „Late Outgrowth Endothelial Cells“ (OECs) beobachtet werden. 
Im Gegensatz dazu waren die halb-steifen und steifen Substrate für die Kultivierung von 
allen getesteten humanen Zelltypen geeignet und erlaubten die komplette mesodermale 
Differenzierung von AT-MSCs und PD-MSCs Zellschichten. 
Im letzten Teil der Arbeit habe ich optimale Bedingungen für die Erzeugung und das 
Ablösen von PD-MSC Zellschichten etabliert. Um eine PEM-Architektur zu finden, 
welche die Zellschichten während des Wachstums minimal beeinträchtigt, entschied ich 
mich steife (PAH/PSS) Beschichtungen zu verwenden. Solche Beschichtungen 
unterstützten die Bildung von PD-MSC Zellschichten ohne chemische Versteifung. 
Außerdem konnten Zellschichten entweder durch Anwendung eines elektrochemischen 
Stimulus im Bereich von 1.8 mV oder durch eine saure Umgebung (lokaler pH 4) von 
der Oberfläche freigesetzt werden. Lebensfähige PD-MSC Zellschichten welche von 
(PAH/PSS) Substraten abgelöst wurden, konnten wieder auf Zellkulturschalen anhaften 
und dort in Richtung Adipogenese und Chondrogenese differenziert werden. 
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Abschließend kann festgehalten werden, dass PEM basierte Substrate sich als nützlich 
für die Kultivierung und Differenzierung von PD-MSCs erwiesen. Da diese Plattform das 
elektrochemisch und pH-vermittelte Schälen von Zellschichten ermöglicht, könnte sie in 
Zukunft für die Erzeugung homogener sowie gemusterten Zellschichten, welche zu 
gewebeähnlichen Konstrukten zusammengebaut werden, zum Einsatz kommen. 
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CHAPTER 1 
INTRODUCTION  
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1.1. REGENERATIVE MEDICINE IN THE CONTEXT OF MODERN SOCIETY 
Despite of the fact that the human body possesses the inherent ability to regenerate 
some specific cell populations and tissues, such as those of the liver, kidney, skin, and 
ribs, for instance, it is still very poor in terms of complete self-regeneration. In contrast 
to the majority of primitive species, high mammalians and humans suffer from the 
inflammation and scar tissue formation that have replaced true regenerative abilities. 
For this reason, detriments such as damage, dysfunction, disease, or aging often lead to 
severe problems associated with morbidity, invalidity and mortality. Statistics show that 
annually, millions of patients worldwide require the structural and functional 
regeneration or replacement of organs and tissues. 
The idea of generating live structures, from artificial tissues and organs to complex 
living organisms, was a matter of myths and dreams throughout the history of 
humankind. Starting from very early historical periods, legends concerning spontaneous 
wound healing or the creation of independent life without sexual reproduction, such as 
biblical tale about Eve emerging from Adam‟s rib or the myth about the regeneration of 
Prometheus‟s liver, illustrate an understanding of regenerative medicine from a naïve 
point of view [1]. However, parallel to such mythologies, the first efforts to reinstate the 
function of injured or lost body parts using non-living prosthetic devices (such as metal 
or ivory teeth and wooden limbs, for instance) were performed starting from antique 
times [2]. 
In early 1950‟s, as the concept of immunosuppression gained traction and relevant 
drugs became available, surgical transplantation became an ultima ratio for the 
problem of organ and tissue replacement. The combination of well-established surgical 
expertise with immunosuppression led to the rapid advancement of methods for solid 
organ transplantation. The first successful kidney transplant, between two identical 
twins, took place in 1954, followed by the first liver and lung transplant in 1963, and 
pancreas transplant in 1966 [3-5]. The first successful transplant of a human heart, in 
1967, marked an important milestone in the era of mature, fully-functional organ 
transplantation [6]. The next quantum jump in transplantation occurred just one year 
later, with the first successful human bone marrow transplant in 1968 [7].  
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Yet, despite continuous development, the possibilities of surgical transplantation are 
still limited by its aging demographic base, increasing donor shortage, and associated 
post-operative complications. Modern transplantation is further impeded by the 
absence of ideal, artificial substitutes that can completely mimic native human organs 
and tissues. The development of new therapies for the treatment of aged, diseased, or 
damaged human tissues and organs is absolutely necessary [8-10]. 
In the 1990‟s, the field of regenerative medicine, and tissue engineering in particular, 
became a promising alternative to traditional homologous transplantation [11]. Tissue 
engineering relies on the use of cellular and acellular components that either induce 
host tissue and organ regeneration or allow for the replacement of damaged tissue and 
organ by de novo - generated tissue substitutes. However, success in regenerating native 
tissues or their tissue-engineered substitutes depends on a thorough understanding of 
human organogenesis. Therefore, harnessing processes witnessed in both native organ 
formation as well as vascularization for artificially-induced tissue regeneration will 
provide the best chance of success in overcoming native organ dysfunction while 
establishing integration of the engineered substitute with the host vasculature [12].  
1.2. HUMAN EMBRYONIC DEVELOPMENT AND ORGANOGENESIS 
Human evolution has resulted in the establishment of multicellular tissue structures 
and organs optimally adopted for specific functions in the body [13]. The formation of 
these highly organized and functionally integrated structures occurs mainly during 
organogenesis, the period of the intrauterine embryonic development. Organogenesis, 
starting from the fertilized oocyte (zygote), is characterized by a plethora of tightly 
coordinated events such as cell proliferation, differentiation, migration, and 
rearrangement. Immediately after its formation, the zygote undergoes a series of 
extremely rapid mitotic divisions wherein its cytoplasm is divided into numerous cells, 
forming a spheroid known as blastocyst. The inner cell mass (ICM) of the blastocyst 
consists of 70 to 100 pluripotent cells, also known as embryonic stem cells, that give rise 
to all differentiated somatic cell types in the adult body. These cells form the 
embryoblast as well as the outer trophoblast cell layer, which forms the placenta. 
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Reorganization of the blastocyst, ICM through gastrulation, leads to the formation of 
three definitive germ layers: the ectoderm, endoderm and mesoderm. From these layers, 
cells start to rearrange and develop the grounds of organs and complex tissue structures. 
Under the guidance of specific soluble molecules and growth factors, cells from each 
germ layer differentiate into a subset of specific cell types. The ectoderm gives rise to 
skin cells, neurons, pigment cells, the lens of the eye, epithelial structure of the mouth 
and anus, pituitary gland, and parts of the adrenal glands. The endoderm develops into 
cells of the lung, thyroid gland, thymus, pancreas, and liver, and additionally forms the 
lining of the gastrointestinal and respiratory tracts and bladder. The mesoderm is 
develops into cardiac, skeletal, and smooth muscle cells, tubule cells of kidney, the 
urethra, gonads, bone, cartilage, and fat cells as well as bone marrow and red blood cells 
[Figure 1].  
 
 
 
Figure 1: Differentiation of three germ layers towards different tissue types. Picture 
adopted from [13]. 
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For the formation of functional tissues, cells derived from the different germ layers will 
have to reassemble in a highly specific arrangement. For example, in human skin, the 
epidermis is derived from ectoderm while the dermis is of mesodermal origin. 
In summary, human organogenesis represents a complex cascade of closely connected 
physiological and anatomical processes leading to the subsequent development of 
specific cell types, tissues, organs, organ systems, and finally, the whole organism. 
Various stem cells, growth factors, and the extracellular matrix are key players in 
organogenesis [14].  
1.3. KEY FACTORS REGULATING ORGANOGENESIS 
The size of organs and of the whole organism closely related to the total cell mass, which 
depends on both the size and total number of cells.  Organ and body size are determined 
by four continuous, cellular processes that all take place during organogenesis: 
proliferation, migration, differentiation, and apoptosis. During organogenesis, these 
processes are tightly regulated and controlled by numerous intracellular programs and 
extracellular signals. The extracellular signals that regulate cell size and cell number are 
normally soluble secreted proteins, proteins bound to the cell surface, or components of 
the extracellular matrix (ECM). They can be divided operationally into three main 
classes: mitogenes, growth factors, and survival factors [15]. In early development, some 
growth factors are provided to the embryo by the maternal system. In late embryonic 
development, growth factors are produced within the embryo itself [16, 17].  
Mitogens are a specific group of more than fifty proteins that normally stimulate cell 
division during organogenesis. However, depending on environmental circumstances 
and the specific cell type, they can also be involved in cell growth, survival, migration, 
and differentiation. One of the first, most famous mitogens to be discovered is platelet-
derived growth factor (PDGF). PDGF stimulates division of many cell types, including 
fibroblasts, smooth muscle cells, and neuroglia cells. Another mitogen, epidermal 
growth factor (EGF), acts on the division of epidermal, epithelial, and non-epithelial 
cells. Erythropoietin is an example of a marrow-specific mitogen, responsible for only 
inducing red blood cell precursor proliferation [15].   
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Like mitogens, extracellular growth factors are bound to cell surface receptors. These 
factors activate intracellular signalling, stimulating growth and increase in cell mass by 
promoting protein synthesis. Depending on the function, different types of growth 
factors exist. For instance, progression growth factors, such as endothelial growth factor 
(EGF) and insulin-like growth factor I (IGF-I), which guide the cells through the stages 
of cell cycle [18]. Inhibitory growth factors govern the tissue and organ enlargement. A 
representative example of this category is myostatin, a member of the transforming 
growth factor β (TGF-β) family that normally inhibits the proliferation and promotes 
fusion of myoblasts. Competitive growth factors are multifunctional secreted proteins 
with a wide variety of effects acting as both paracrine and autocrine signals. Competitive 
growth factors are responsible for molecular communications between different cell 
types, prevention of cell proliferation beyond excessive population density, and correct 
development of various tissues and organs [19]. For example, when interfaced with 
sonic hedgehog (SHH), competitive factors of fibroblast growth factor family, such as 
FGF7 and FGF10, regulate epithelial-mesenchymal interactions (EMI) [Figure 2].  
 
Figure 2: Molecular communications between different cell types during organogenesis. 
Picture modified from [1]. 
These EMI are critical for the development of epithelial-based structures such as 
seminal vesicle, salivary gland, and ventral prostate [20, 21]. Furthermore, FGF10 is 
also important for lung, thyroid, pituitary, pancreas, and lachrymal gland development 
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[22-26]. Survival factors are presumably responsible for the maintenance of the 
functional activities of stem cells. Bone morphogenic protein (BMP) is one of the 
survival growth factors. It usually binds cell-surface receptors and allows the cells to 
undergo pre-committed differentiation without inducing any real differentiation. BMPs 
promote cell survival by suppressing apoptosis [15]. However, specific genes and 
corresponding proteins that mediate survival are still poorly defined.  
In summary, growth factors play an important role during organogenesis: they are 
responsible for the regulation of molecular mechanisms involved in the control of 
embryonic growth. Even a small perturbation of these growth factors can lead to the 
formation of diseased or abnormal foetuses. For example, shift in the production IGF-I 
can lead either to growth retardation or to macrosomia [27, 28]. 
As was mentioned above human tissues and organs represent multicellular 
arrangements with rather complex anatomical architecture. In order to generate 
functional tissues, the correct arrangement and organization of different cell types is 
necessary. The architecture of tissues is supported by the extracellular matrix (ECM), a 
cell-secreted compartment mainly composed of highly viscous proteoglycans damping 
the cells, fibrillar and non-fibrillar matrix proteins providing strength and elasticity, as 
well as soluble adhesive matrix-associated proteins binding the cells via integrin 
receptors [14]. Initially seen as an inactive scaffold, it became increasingly obvious that 
ECM components immobilized morphogenetic cues and provided important 
information to embedded cells [14]. Cells, on the other hand, continuously remodel the 
ECM such that the matrix composition changes over time [Figure 3]. During 
morphogenesis, when tissues and organ shapes are established, remodelling processes 
lead to the formation of instructive cues that guide the cell movement, rearrangement, 
and the formation of patterns. Therefore, the correct composition of ECM components 
(such as fibronectin, collagen, and laminin) and organ specific molecules (such as 
nephronectin) must be coupled with the expression of the corresponding receptors in 
order to incite correct tissue and organ development. The absence or imbalance of 
specific components and factors during ECM deposition or degradation will lead to 
malformation or failure in organ development [29].  
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Figure 3: Structure of extracellular matrix (ECM) by mammalians. Picture adopted from 
[14]. 
1.4. POSTNATAL DEVELOPMENT AND HOMEOSTASIS 
Embryonic development results in the complete formation of functional tissues and 
organs as well as determination of specific cell fate. Following the latter, cell 
proliferation leads to the growth of the whole organism through the enlarging and 
remodelling of tissues and organs. For enlargement of an organ, cell proliferation should 
be always accompanied by cell division, otherwise cells would get progressively smaller 
and total cell mass will not increase. Likewise with the process of organogenesis, control 
of cell growth and proliferation during the postnatal development is guided by 
extracellular growth factors and mitogens [15]. Finally, growth of the human organism 
is terminated during adolescence. However, despite completion of overall growth, any 
tissue injury, infection or necrosis in the organism can activate specific mechanisms of 
cell renewal called homeostasis. During homeostasis, constant cell production is 
required to sustain the replacement of damaged cells and tissue domains, thus 
balancing continuous cell death and maintaining native tissue [30]. Homeostasis 
represents a mechanism for the elimination of damaged or age-differentiated cells and 
their replacement by tissue-specific progenitor cells, referred to as adult stem cells 
[Figure 4].  
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Figure 4: Mechanism of cell turnover in solid organs. Picture modified from [31]. 
Adult stem cells are believed to reside in almost all tissues of the body and are thought 
to be localized in specific compartments called stem cell niches. Stem cell niches are 
described today as discrete and dynamic functional domains that are responsible for 
maintaining stem cells in their native status, replenishing the population of proliferative 
progenitor cells that give rise to differentiated cells, and governing tissue homeostasis 
under diverse physiological (development and aging) and pathological (injury and 
disease) conditions [32]. 
Architecture of the stem cell niches is only partially known. All stem cell niches 
represent defined anatomical compartments composed of the stem cell itself, micro-
environmental stromal cells, and ECM proteins [32]. Additionally, the haematopoietic 
stem cell (HSC) niche contains blood vessels. All of these components play a defined 
role and are responsible for the correct function of the niche [32]. Micro-environmental 
stromal cells provide a specific barrier shield for the stem cells and defend them from 
signalling cues that would induce migration or differentiation. These stromal cells are 
also responsible for interactions between stem cells. The ECM proteins might provide 
mechanical and specific cell adhesion signals and support the structure of the niche. The 
blood vessels provide signals for the recruitment of circulating cells into the niche 
[Figure 5]. Anatomically, stem cells residing on the basal membrane of the niche are 
connected through homologous cell-cell interactions with micro-environmental cells, 
which build a regulatory environment [Figure 6].  Functionally, stem cell niches 
control the rate of stem cell proliferation and prevent excessive stem cell growth, 
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determine the fate of the stem cell daughter cells, and protect stem cells from death by 
exhaustion. Niches provide specific signals to their stem cells in form of the intrinsic 
secreted factors or surface molecules [Figure 7].  
 
 
Figure 5: Hypothetical structure of the stem cell niche. Picture modified from [32]. 
 
 
 
Figure 6: Residing of stem cell in the niche. (A) Three dimensional structure of the niche. 
(B) Regulatory microenvironment of the niche. Picture modified from [32]. 
 
 
Figure 7: Supposed mechanism of niche contribution to dysplastic cell growth. (A) Normal 
occupation of stem cell niche, (B) Ectopic occupation by another cell type in case of the 
vacancy in the niche, (C) Disordered state of tissue organization and control improved by 
proliferative and de- differentiative signals. Picture modified from [32].  
A 
B 
A 
B 
C 
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Stem cell niches do not always incorporate the aforementioned components. Generally, 
they represent various entities containing different combinations of niche components 
and multiple inputs, all of which are established for accomplishing of the exquisite 
control for particular type of stem cells involved in homeostasis.  
Depending on the specific function, stem cell niches can be divided into three sub-types: 
simple cell niches, complex cell niches, and storage niches [Figure 8]. The simple cell 
niche represents a micro-environment in which one stem cell type is locked through 
adhesion junctions and integrin-mediated interactions to the extracellular matrix. In 
this niche, stem cells receive paracrine signals that promote their growth while 
inhibiting differentiation. The complex niche contains different stem cell types at once. 
The storage niche contains specific resident stem cells that activate in case of trauma 
[33]. These cells subsequently divide and migrate to repair injured tissue.  
A    B    C 
 
 
Figure 8: Proposed types of the cell niches. Simple niche (A), complex niche (B), and 
storage niche (C). Picture modified from [33]. 
Only strongly-balanced interactions between all components sharing the niche ensures 
the maintenance of the stem cell phenotype and guides differentiating daughter cells 
away from the niche [34]. After leaving the niche, stem cells are no longer controlled by 
intrinsic and extrinsic niche derived factors that maintain their undifferentiated 
phenotype. As a result, they start to differentiate, first into transiently amplifying 
progenitor cells, followed by continuously amplifying progenitor cells. Depending on 
morphogenetic cues, progenitor cells will further differentiate along a specific lineage 
until achieving a terminally differentiated adult phenotype. At this stage, terminally 
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differentiated cells execute specialized functions and their proliferative potential is 
restricted to a few cycles.  
Depending on the homeostatic situation, niches can appear for the recruitment of stem 
cells, which are necessary for the particular anatomic location in a concrete tissue or 
organ. Once formed, niches are responsible for local regenerative cues and interactions 
with supporting stem cells. Three different mechanisms for specific stem cell niche 
establishment have been proposed. The first mechanism is associated with 
embryogenesis. In this case, the niches are built from heterologous cell types during the 
time of organ formation and remain stable during growth, adolescence, and homeostatic 
periods independent of stem cell presence during their occupation [32]. The second 
mechanism might be described as post-embryonic co-development of stem cells, with 
micro-environmental cells with following formation of the niches because of their close 
localization and continuous interactions [32]. The third mechanism is based on the 
ability of some cell types, such as hematopoietic stem cells (HSCs) or primordial germ 
cells (PGCs), for instance, to form stem cell niches during proliferation. In this case, 
organisms could customize different niches in order to support symmetric or 
asymmetric division, facilitate rapid proliferation, impose stem cell quiescence, and bias 
differentiation of progenitor cells towards specific lineage [35].                    
Despite to the functional diversity between stem cell niches, their key components 
remain the same across different tissues and organs. In all cases, the niche provides 
structural and trophic support as well as topographical information and the appropriate 
physiological cues, all of which are necessary for the regulation of stem cell function 
[35].         
The exact number of specific niches that harbour stem cells and maintain continuous 
cell turnover during life cycle is still unknown. However, at least three types of stem cell 
niches, which actively contribute to homeostasis, are becoming elucidated [36]: the 
niche of intestine, known as the interstitial stem cell niche (ISCN) [36], the hair follicle 
epidermal stem cell niche (HFSCN) [37, 38], and the hematopoietic stem cell niche of 
the bone marrow (HSCN) [39]. All of these stem cell niches share the common 
properties described above [36]. At the same time, intricate signalling of interstitial and 
follicle epidermal niches is dependent on the surrounding mesenchymal cells [36, 40]. 
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The MSC niche itself also plays a very important role in homeostasis [35, 36, 41].  Based 
on the fact that MSCs isolated from the vast of postnatal tissue types expressed alpha 
smooth muscle actin (α-SMA) and pericytes-associated cell-surface marker 3G5, a 
perivascular nature of MSC niche was hypothesized [42]. According to the perivascular 
theory, MSCs localized in the perivascular niche are distributed throughout the body 
and can easily access to all tissues in case of injury. However, in vivo experimentation is 
still required to test this theory. 
Taken together, human tissue homeostasis represents a dynamic equilibrium which 
maintains an internal status quo within a defined tissue of an organism through the 
continuous regulation of cellular proliferation and death as well as control of metabolic 
function. A misbalance between cell renewal and cell death during homeostasis can lead 
to disease or even death of the individual. A stem cell niche is a micro-environmental 
unit to maintain stem cells and to replenish the pool of progenitor cells during the 
homeostatic regeneration of tissues and organs. They are thought to be involved in the 
process of tightly regulating the self-renewal of the adult stem cells. Recent 
investigations show that different niches are adopted to their unique function and even 
small misbalance between structural parts of the niche can lead to pathological 
degeneration of tissue, aging, decrease of regenerative potential, and malignancy [35]. 
For example, if the production of liver cells outweighed their death by only 1%, liver 
weight would be equal to initial body weight within a period of 6 to 8 years [33].  
1.5. ROLE OF MESENCHYMAL STEM CELLS IN TISSUE HOMEOSTASIS 
Post-natal tissues of the human body harbour different numbers of progenitor cells, all 
of which can give rise to cell types of the specific tissue in which they reside. Such cells 
were first isolated from human bone marrow (BM) and described as marrow stromal 
cells (MSCs) in 1970‟s [43, 44]. Recently, cells with similar properties were isolated from 
adipose tissue, epidermis, liver, pancreas, brain, dental pulp, spinal cord, etc. [45, 46]. 
Unlike the totipotent embryonic stem cells (ESCs) which are responsible for embryonic 
development and foetal growth of an organism, multipotent adult MSCs contribute to 
homeostasis as well as to regeneration of diseased organs and damaged tissues. 
Moreover, during the process of tissue homeostasis, MSCs are also involved in the 
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processes of self-tolerance and affect the immune system, which is critically important 
for tissue regeneration [47]. The exact origin and primary location of MSCs participating 
in tissue homeostasis still remains debatable and unclear.  
Three different hypotheses exist with regards to the specific location of these cells in an 
organism. The first hypothesis suggests that MSCs are located in only a few specific 
tissues or organs. Upon homeostatic demand, they would exit their sedentary locations 
and migrate to other tissues and organs in order to replenish the apoptotic adult cell 
populations in case of physiological turnover or pathological necrosis [47]. The second 
hypothesis is based on the suggestion that MSCs with very similar immuno-phenotypic 
and functional properties reside in all postnatal tissues of the body, especially in the 
form of different tissue-intrinsic progenitor cells that can be recruited during 
regeneration [47]. The third hypothesis suggests that MSCs reside in a perivascular site. 
In case of disruption of blood vessels or neighbouring tissues, tissue specific progenitors 
can be liberated in form of pericytes-like cells, which subsequently migrate to the site of 
need, proliferate, and secret bioactive factors in order to protect and regenerate the 
specific tissue [47]. Based on this hypothesis it has been speculated that pericytes could 
be an in vivo source of mesenchymal cells for in vitro applications [48]. One argument 
that supports this view is that pericytes can give a rise to adult cell types such as 
adipocytes [49], chondrocytes [50], and osteoblasts [51].   
The main criteria that distinguish adult MSCs from end-differentiated, adult cell types 
are their specific stemness properties (properties that confer the ability to self-renew 
and to differentiate into cells of different lineages). Stemness include: the ability for self-
renewal, plasticity or differentiation potential, and regenerative potential. 
Self-renewal is the ability of stem cells to produce daughter cells with identical stem cell 
features as the mother cell. Stem cell division can take place either symmetrically or 
asymmetrically. In case of symmetric division, both daughter cells have the same fate 
and become new stem cells. In the case of asymmetric division, one daughter cell 
becomes a new stem cell while another one will differentiate into a specific cell type. 
Whether the balance between symmetrical and asymmetrical divisions or the number of 
divisions is responsible for the generation of appropriate amounts of stem cells and 
differentiated cells in an organism at this stage remains unclear. Many different 
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pathways might be involved in stem cell self-renewal and some of these are well 
described, but others are still debatable or unknown. Self-renewal regulation can be 
coordinated by cell cycle and proliferation. Curiously, the same pathway mechanism can 
stimulate differentiation of one cell type while being involved in the maintenance of self-
renewal potential by other cell types. For example, the process of stem cell renewal can 
be regulated through the chromatin structure by polycomb group proteins (PcG), which 
represses the transcription of genes that regulate differentiation. Examples include Bmi-
1, Mel-18, and Rae-28. In another regard, depending on the specific situation, self-
renewal can be also involved such signalling pathways as Notch, Wnt, and Hedgehog.  
Differentiation potential or plasticity is a property in which stem cells become restricted 
in their capacity to form a variety of different cell types; rather, they specialize to form 
more specific cell types that fulfil particular, focused functions within the body. The 
spectrum of cell types, towards which adult stem cells can differentiate, is determined by 
their potency. Adult stem cells, which can form only one particular cell type within one 
particular lineage, are unipoptent. Tissue specific MSC-like cells are multipotent and 
can be differentiated into multiple specialized lineages, such as adipogenic, 
chondrogenic, osteogenic, or myogenic, for instance. Adult stem cells can be 
differentiated towards a broad spectrum of adult cell types within one particular lineage, 
such as neural stem cells or hematopoietic stem cells, and are referred to as oligopotent 
stem cells.  
1.6. TISSUE REGENERATION 
Tissue regeneration, in contrast to the genetically programmed, slow-cycling process of 
homeostasis, involves the secretion of exogenous factors that cause acute damage and 
can provoke a strong inflammatory response – wounding [31]. Tissue repair consists of 
several steps [Figure 9].  Immediately following injury, the blood coagulation cascade 
is activated by platelet tissue factor called thrombokinase. The blood clot is normally 
formed within several minutes by aggregation of fibrin and thrombocytes. At the same 
time, blood vessels surrounding the injury site are constricted in order to reduce 
haemorrhage. Stimulated by platelet-released factors, vasodilatation and vascular 
permeability are induced in neighbouring blood vessels.  
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Figure 9: Stages of tissue regeneration process: (A) Inflammation, (B) New tissue 
formation, (C) Tissue remodelling and scarification. Picture adopted from [52]. 
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The activation of the clotting cascade leads to the formation of a fibrin plug, which, in 
combination with fibronectin, serves as provisional matrix for the subsequent 
recruitment of inflammatory cells and migration of tissue resident MSCs. At the second 
stage, inflammatory cells, such as neutrophils and macrophages, are recruited through 
release of the mitogenic and chemotactic factors, such as platelet-derived growth factor 
(PDGF), transforming growth factor beta (TGF-β), and tumour necrosis factor alpha 
(TNF-α). After the destruction of pathogenic microorganisms by inflammatory cells, 
surrounding endothelial cells start to form new blood vessels. At the third stage, tissue 
resident MSCs migrate towards the site of injury and together with macrophages and 
fibroblasts replace the provisional matrix with granulation tissue. In the fourth stage to 
the wound becomes contracted. [47]. The final stage of normal wound healing process is 
formation of the scar, which appears through the stimulation of collagen synthesis [52, 
53]. The mechanisms involved in MSC migration during tissue regeneration are still 
debatable. A first hypothesis suggests that specific receptors, facilitating trafficking of 
MSCs and regulating their following adhesion and infiltration, are located in the MSC 
niche. They are immediately activated after injury through the release of factors, such as 
stem cell factor (SCF) or stromal-derived factor 1 (SDF-1). A second hypothesis proposes 
that integrins, selectins, and chemokine receptors expressed on the surface of MSCs, are 
responsible for MSC migration to the injury cite. The third hypothesis is based on the 
assumption that MSCs passively reside in capillaries and micro-vessels directly interact 
with accessory pericytes, thus recruiting MSCs to the injury site through release of 
soluble growth factors and trophic cytokines [54-56]. The latest studies also suggest that 
MSCs secrete trophic, immunosuppressive and antifibrotic factors which minimize the 
extent of damage and lead to the reduction of inflammatory response of the organism. 
The capacity for self-regeneration in humans is directly connected with human 
complexity. Depending on parameters such as the age of an individual, type of tissue, 
accompanying diseases, or genetic disposition, the efficiency of regeneration can vary 
drastically. The regenerative potential of all human tissues and organs is strongly 
dependent on the rate of cell turnover and is regulated through the contribution of the 
tissue specific (MSCs) and hematopoietic (HSCs) stem cells [57]. According to their 
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regenerative potential, all human tissues and organs can be divided into three categories 
[Figure 10].  
 
 
Figure 10: Contribution of stem cells to homeostasis. Picture modified from [57] 
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The first category contains organs and tissues that possess a high cell turnover, a high 
regenerative capacity, and a prominent stem cell compartment such as blood, skin, and 
gut. The second category is comprised of organs and tissues with low cell turnover and 
high regenerative potential. An example lies with skeletal muscles, because they are 
unable to proliferate and generate new tissue, but can recruit resident stem cells for 
turnover and regeneration. Organs of the third category, such as the brain and heart, 
show low endogenous repair capacity, low cell turnover and low regenerative potential.  
The most famous example of self-regeneration in human organs lies with the liver. The 
human liver is a unique organ which can regenerate its whole mass from any remaining 
fragments smaller than 25% of the native organ mass [58]. This ability is due to the 
hepatocyte capacity for self-renewal. Resection of the liver induces proliferation of 
remaining hepatocytes until the whole mass of the organ is restored [59]. Interestingly, 
the liver never overgrows its original size; instead, it is adapted to the size of an 
organism as demonstrated by transplantations of liver lobes into children. This process 
is thought to be regulated by the circulating homeostatic factor, the hepatocytes growth 
factor. In addition to the liver, the fingertips, ribs, and kidney are other examples of 
human tissues and organs with the potential for self-regeneration [60-62]. 
The regeneration of the damaged tissues and organs induced by the organism itself is 
one of the most complex and uncontrollable biological processes that takes place during 
human life. However, even though the human body possesses an inherent ability for 
homeostatic cell turnover as well as regeneration of selected cell and tissue types, 
healing might often be delayed or excessive. Delayed healing processes normally lead to 
the formation of chronic wounds, while excessive healing processes are related with 
formation of non-functional fibrotic tissue. Due to these issues, the inherent 
regenerative potential of an organism might be insufficient for complete restoration of 
the organ or tissue function in case of pathological disease and trauma. Traditional 
surgical methods of organ and tissue transplantation as well as use of biomechanical 
devices and artificial organ-like structures are also imperfect solutions for the 
restoration or support of damaged organs and tissues. Thus, the establishment of new 
strategies for the transformation of fibrotic healing processes towards functional tissue 
regeneration are absolutely necessary [Figure 11].  
28 
   
 
Figure 11: Advantages of artificial organogenesis comparable with tissue regeneration. 
Picture adopted from [52]. 
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1.7. REGENERATIVE MEDICINE 
Regenerative medicine is an extended field of medicine that aims to induce healing for 
the replacement of defective tissues and organs. The term “tissue engineering” was 
classically used in the context of surgical manipulations and the application of 
prosthetic devices or biomaterials for tissue or organ reconstruction. In 1987, Langer 
and the Vacanti brothers introduced a modern definition of tissue engineering: “Tissue 
engineering is multidisciplinary field combining principles of life science with methods 
of engineering for the development of functional biological substitutes that restore, 
maintain or improve tissue and organ function” [11, 63] 
On one hand, a modern definition of regenerative medicine states that the ultimate goal 
is “to replace living functional tissue with living functional tissue that is designed and 
constructed to meet the needs of each individual patient” [64, 65]. On another hand, the 
final goal of regenerative medicine can be described as implementing a functional and 
structural restoration as well as de novo engineering and substitution of diseased or 
damaged human tissues and organs.  
The main approaches of regenerative medicine were introduced almost two decades ago 
and are based on two different principles: tissue regeneration and tissue engineering. 
Dependent on specific clinical demand, these approaches can be realised using many 
specific strategies and methods which have some advantages and some disadvantages 
[Figure 12].  
 
Figure 12: Main approaches of regenerative medicine. 
Most useful strategies and methods of regenerative medicine include the 
transplantation of acellular substances and biomaterials that promote tissue 
regeneration, infusion of purified and mixed cell suspensions, and transplantation of 
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bioengineered structures which represent combinations of specific cell types and 
materials [64-66].  
1.8. STRATEGIES FOR TISSUE REGENERATION 
Tissue regeneration is mainly based on the repair of damaged host tissues by inducing 
the tissue‟s own regenerative potential. The most popular strategies include the infusion 
of purified or mixed cell suspensions, transplantation of acellular substances inducing 
tissue regeneration, and transplantation of developing organs.  
The direct transplantation of isolated cells is based on the assumption that cells can 
directly integrate into tissues and support the regenerative processes if they are placed 
into specific microenvironment. Typically, direct cell transplantations are performed 
either topically or systematically through the injection of autologous or allogeneic cell 
suspensions. Such procedures avoid complicated surgical interventions and permit 
different cell manipulations before injection [67]. The disadvantages of direct cell 
transplantation include low tissue integration and high death rate of injected cells as 
well as little control over cell functions after transplantation. Furthermore, due to the 
high risk of post-transplant complications, such as associated infections, veno-occlusive 
disease, mucositis, graft-versus-host disease (GVHD), and graft-versus-tumour effect 
(GVT), this procedure is traditionally reserved for patients with life-threatening diseases 
[11, 64]. 
Transplantation of tissue-inducing substances is based on the delivery of specific signal 
molecules, such as growth factors, to the damaged organ or tissues in order to stimulate 
organ/tissue self-regeneration. On one hand, this method is minimally invasive and 
easily controllable, while on another hand, its efficiency is strongly dependent on the 
purification and large-scale production of appropriate growth factors as well as 
development of specific delivery strategies, which will provide tissue inducing agents 
precisely to the targeting site [68]. 
Transplantation of entire or partial developing embryonic organs into adult recipients is 
known as the intracorporeal tissue regeneration approach. In contrast to strategies that 
employ initially desegregated donor cells, cells in transplanted developing organs 
remain in their natural microenvironment and can thus continue to fulfil their 
31 
   
physiological function. This method has been experimentally established for the 
reconstruction of kidney. Due to the avascular nature of renal tissue during the initial 
stages of development, this organ possesses very low potential of immuno-rejection 
[69]. Results showed that parts of embryonic kidneys as well as whole organs could be 
successfully implanted into the adult host [70, 71]. However, due to the serious ethical 
and practical problems associated with the use of material derived from human 
embryos, the application of embryonic organ rudiments is not a clinical option at the 
moment [1]. 
1.9. STRATEGIES FOR TISSUE ENGINEERING 
The tissue engineering approach is based on the replacement of damaged host tissues by 
de novo-generated, functional, tissue-like substitutes. Classical tissue substitutes can 
arise from cells, biomaterials or their combinations. Such substitutes should integrate 
into the patient as soon as possible and be allowed to immediately begin restoration of 
specific tissue or organ function [11, 63, 72]. Tissue-engineered substitutes can be 
generated ex vivo outside of the body (extracorporeally) or in situ inside of the body 
(intracorporeally). Unlike ex vivo tissue engineering, where the whole process of tissue 
formation and partially also tissue remodelling occurs outside the body, in situ tissue 
engineering initiates and completes the generation of tissue substitute inside the body.  
Initially, ex vivo tissue engineering strategies were limited to simple tissue substitutes 
fabricated under static cell culture conditions in vitro before implantation. Today, 
dynamic devices, such as flow-through systems and complex bioreactors are employed 
to generate functional tissue substitutes prior to the transplantation. In order to form 
such constructs, in vitro expanded cells are seeded into 3D scaffolds that might provide 
the proper physicochemical and biological cues to support cell proliferation and 
differentiation. The cell-seeded scaffolds are incubated in a bioreactor with specific 
conditions (flow) to stimulate the correct development and growth of the tissue 
substitute. Once the cellular construct has consolidated its structure and reached the 
desired functionality, the ex vivo generated tissue substitute will be removed from the 
bioreactor and subsequently transplanted into the living organism. Although, two ex 
vivo generated scaffold-based tissue substitutes, tissue engineered heart valves and 
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blood vessels, are now reaching late pre-clinical testing [73, 74], major limitations 
restrict the use of ex vivo tissue engineering strategies for other applications. The 
diffusion of nutrients and waste products as well as limited gas exchange does not allow 
for the fabrication of large tissue substitutes and complex artificial organs. Furthermore, 
the preservation of viability and functionality of ex vivo generated tissues post 
transplantation requires a preformed functional vascular system. Finally, the 
inflammatory response towards biomaterial remnants might inhibit the successful 
integration of the transplant. 
In situ tissue engineering is based on the general idea that the human body is the best 
bioreactor, providing ideal conditions for tissue development and regeneration. The four 
most prevalent approaches of intracorporeal tissue engineering include: transplantation 
of individual cells in form of purified cell suspensions, transplantation of acellular 
inducing substances stimulating regenerative processes of the target tissue, 
transplantation of developing organs, and transplantation of cells attached to the 
biocompatible scaffolds [66]. 
The concept of scaffold-based tissue engineering corresponds to physiological tissue 
remodelling and morphogenesis [Figure 13].  
 
Figure 13: Spontaneous remodelling of embryonic cell cultures cultured in vitro. (A) 
Organization of polarized cyst by foetal epithelial cells cultured in 3D matrices. (B) 
Organization of epithelial and mesenchymal compartments by mixtures of foetal lung cells 
cultured in 3D matrices. Picture modified from [1]. 
A 
B 
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Under appropriate environmental conditions dissociated cells can reassemble in vitro 
into structures that resemble the native tissue [75]. Furthermore, cells in native tissues 
are adherent and located within the cell instructive three-dimensional viscoelastic ECM. 
In this milieu matrix, associated signalling cues and a three-dimensional arrangement of 
cells are provided. These cell-matrix and cell-cell interactions play an important role in 
tissue development, maintenance and homeostasis, as well as tissue regeneration [76].  
The use of matrices, which mimic some of the signalling properties of the ECM and 
provide mechanical support for de novo formation and structural stabilization of 
engineered tissues, can be considered as classical algorithm of tissue engineering [77, 
78]. Technically, scaffold-based tissue engineering is performed by placing cells on or 
within bio-instructive scaffold followed by transplanting this cell-scaffold construct into 
the recipient. Until recently, it was not possible to correctly mimic the anatomical 
structure and physiological functions of ECM for guiding morphogenesis. Novel 
technological platforms that allow for both proper positioning of cells and matrix 
components as well as concurrently defining stem cell fate will make controlled, guided 
morphogenesis possible. [78]. Initial attempts to form meaningful artificial structures 
consist of spotting and printing cells and materials in 3D architectures [79]. 
Scaffold-free tissue engineering represents an alternative to scaffold-based tissue 
engineering. It is based on the assumption that absence of any biomaterial compartment 
increases the potential of tissue-like structures for correct integration into the body and 
decreases the risk of infections as well as complications related to the foreign body 
reaction. Micro-tissues are an excellent example of a scaffold-free tissue engineered 
structure. Micro-tissues (also termed organoids) represent functional cell aggregates 
sized between 100 and 500 nm in diameter [80]. They are generated from either 
enzymatically or mechanically dissociated tissues [81, 82], cell lines [83, 84], or stem 
cells [85]. Experimental results have shown that micro-tissues can be assembled from 
various cell types such as cardiomyocytes, neurons and chondrocytes [86-88]. 
Organoids have many advantageous properties that make them potentially attractive for 
future clinical use. Due to their relatively large size and extensive ECM, micro-tissues 
are mainly retained at the site of application and have a good grafting potential. 
Moreover, emerging evidence has demonstrated that micro-tissues produce 
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proangiogenic factors, such as VEGF, that potentially support pre-vascularization in 
vitro or induce angiogenesis after implantation [89-91]. Additionally, organoids can be 
used as building blocks for assembling of scaffold-free tissue-like structures, which can 
be produced in moulds of defined shapes. Experiments in animals demonstrated that 
tissue-like patches assembled from single human chondrocyte-composed micro-tissues 
are able to produce a sufficient level of collagen II and adapt to native-like cartilage 
morphology [90]. Despite this promising potential, the micro-tissue approach still 
remains inadequate for direct clinical applications because of difficulties related with 
blood supply and controlling of organoid shape after implantation [92, 93].  
Though regenerative medicine is relatively young compared to other medical disciplines, 
the first successful attempts in the field were demonstrated in the 1970‟s by Dr. John 
Burke and Dr. Iannas Yannos. They generated de novo skin substitutes using collagen 
matrix-supported growth of dermal fibroblasts. At the same time, Dr. Howard Green 
successfully treated burn patients by transplanting sheets of keratinocytes. The clinical 
successes of these efforts as well as their commercial potential led to the new concept of 
extracorporeal tissue generation in vitro and, in the 1990‟s, to the revolutionary idea of 
manufacturing “off-the-shelf” tissue or organ replacements. This was a driving force for 
the organization of the first tissue engineering programs, non-commercial initiatives, 
and commercial companies with the primary aim of overcoming the main problems of 
traditional transplantation [94].  
1.10. MAIN PILLARS OF TISSUE ENGINEERING 
For proper patho-physiological regeneration in situ or the ex vivo engineering of 
functional tissue, a careful selection of specific cell types, biomaterials, metabolic growth 
factors, and biomechanical environmental conditions is crucial. Today‟s tissue 
engineering efforts combine the latest achievements of stem cell research, materials 
science, and nanotechnologies as well as biophysics and bioinformatics. During the last 
two decades, tissue engineering has made tremendous progress. The main pillars for the 
successful development of functional complex tissue and organ substitutes were 
established [Figure 14].  
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Figure 14: Main pillars for successful development of complex tissue and organ substitutes 
Based on their physiological role in vivo, cells are often considered to be the building 
blocks for artificially-induced tissue regeneration. Functionally, cells should have the 
capacity to produce missing tissue components and restore the function of the host 
tissue and organ. For this reason, choosing the appropriate cell type is critical for the 
success of any cell-based therapy.  
Soluble growth factors include cytokines, growth factors, morphogenetic proteins, small 
molecule agonists, steroid hormones and ions. These factors feed into complex, 
interacting networks of signal transduction pathways and regulate cell growth, 
differentiation, and apoptosis. Refer to Chapter 1.4 for more details. 
According to Williams‟ 1987 definition of biomaterials, biomaterials are nonviable 
materials used in a medical device and intended for interactions with biological systems 
[95].  Biomaterials in tissue engineering serve as structural supports or cell adhesion 
sites, and can be engineered for biologically-active molecule delivery. Moreover, 
supporting structures engineered from biocompatible materials can promote viability, 
expansion and incorporation of transplanted cells. Biomaterial properties influence the 
formation of structurally and functionally different products, such as hydrogels or 
porous scaffolds. Biomaterials are very diverse, ranging from hard materials (such as 
Calcium Phosphates) to soft naturally-derived polymers (such as fibrin and collagen) as 
well as fully-synthetic polymers (such as polyethylene glycol).  
Bioreactors are closed, fully controllable systems that play an integral role in the 
cultivation and expansion of cells for extracorporeal tissue and organ generation. 
Bioreactors allow for continuous observation and manipulation during the whole 
process of tissue substitute formation. A tight control over flow, mixing regimen, and 
medium composition, including application of defined amounts of bioactive molecules, 
can be achieved within the bioreactor. Moreover, if needed, bioreactors can hydro-
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dynamically stimulate cells and thereby increase the production of glycosaminoglycans 
or collagens leading to biomechanical stabilization tissue substitutes [64, 96]. 
Depending on the design and type of working system, different bioreactors exist: 
hollow-fibre, perfusion, stirred tank, and rotary.  
1.11. CELL SOURCES FOR TISSUE ENGINEERING 
An ideal cell source should be non-immunogenic, highly proliferative, easily accessible, 
and should have the plasticity for differentiation into a broad range of tissue-specific cell 
types. Furthermore, regenerative therapies should utilize cell sources that allow for the 
extensive expansion of relatively few cells into large volumes of tissue [63]. Depending 
on the developmental stage, cells currently used in tissue engineering can be divided 
into four different classes: embryonic stem cells, adult mesenchymal stem cells, tissue-
specific progenitor cells, and adult tissue specific cells [Figure 15].  
Such cells can be isolated from the host itself (autologous), from a foreign donor of the 
same species (allogenic), from another species (xenogeneic), or derived from an 
immortalized cell line. All of these cell sources have advantages and limitations for use 
in tissue regeneration.  
Some cell types derived from adult primary human tissues, such as muscle cells, are 
relatively accessible, have good proliferation capacity ex vivo, and possess reduced 
immunogenic potential in the case of autologous transplantations. However, other adult 
cell types such as osteoblasts or cardiomyocytes are relatively limited in number. Their 
accessibility and ex vivo propagation are very difficult. Moreover, the harvesting of 
allogenic cells is often invasive, painful for the donor, and associated with the high risk 
of postoperative infection. All these logistical disadvantages and economic 
considerations, namely the high pre- and postoperative costs, decrease the 
attractiveness of allogenic cell transplantations.   
Xenogeneic cells derived from primary animal tissues are almost unlimited in supply 
and have physiological and cytological similarity with primary human cells. For 
example, results of clinical trials revealed that foetal porcine cells can survive and even 
produce insulin when transplanted into human diabetic patients [97]. However, the risk 
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of the retroviral transmission and high immunogenic potential make clinical use of 
xenogeneic cells is controversial.  
 
Figure 15: Different cell sources and ways of implantation in regenerative medicine. 
Picture adopted from [94]. 
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Allogenic and xenogeneic cell lines represent cells that were immortalized through 
incorporation of specific chemical agents or viruses [66]. Cell lines can be expanded to 
an almost unlimited number of cells while removing the need for further isolation. 
However, by indefinitely proliferating cells through uncontrolled genetic modification, 
daughter cells run the risk of diminished function or gaining oncogenic potential. Such 
risks and a lack of knowledge regarding functional limits impede the use of 
immortalized cell lines for in vivo transplantations [98]. As such, immortalized cell lines 
are relegated to in vitro modelling of tissue-like systems. 
In summary, despite the impressive pre-clinical and clinical results of the last two 
decades, adult tissue specific cells and tissue-specific progenitor cells cannot be 
considered sufficient for human tissue reconstruction. Due to the invasive harvesting 
procedure, relatively limited quantities, and restricted proliferative capacity, clinical 
applications of human tissue-specific cells, even in the case of autologous 
transplantations, remain very controversial. Furthermore, because of the high risk of 
immunorejection, today‟s transplantation of allogenic and xenogeneic cells is followed 
by immuno-suppressive therapies [94]. 
 
Stem Cells 
Due to their advantageous properties of self-renewal, immunomodulation, and 
plasticity, stem cells are the most attractive candidates for human tissue engineering 
and cell therapy. There are four main fields for stem cell application in the regenerative 
medicine: cell therapy, in situ tissue engineering, ex vivo tissue engineering, and in vitro 
testing [Figure 16].  
Depending on application, stem cells can be either transplanted directly to the site of 
injury as cell suspension or combined with biocompatible and biodegradable scaffolding 
material prior to transplantation. Stem cells also can serve as building blocks for 
extracorporeal de novo generation of complex functional tissue or organ substitutes. 
Additionally, organotypic cultures containing stem cells can be used as test objects for 
evaluation drug effects as well as for simulation of in vivo physiological and pathological 
processes in vitro. 
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Figure 16: Strategies for application of human stem cells in regenerative medicine. Picture 
adopted from [13]. 
     
Embryonic stem cells 
Embryonic stem cells (ESCs) are a promising cell source for human tissue regeneration 
[99]. These cells are pluripotent and give rise to all somatic cell types in the human 
body. The growth potential of ESCs is almost unlimited because they can divide 
indefinitely [100]. Pluripotent ESCs do not freely exist in the human body; they must be 
isolated either from inner cell mass of the blastocyst or during termination of pregnancy 
form abortive foetal tissues [Figure 17].  
Due to their foetal origin, ESCs express low levels of major histocompatibility complex 
(MHC) I, consequently lacking immunogenic potential [99, 101]. However, the 
spontaneous differentiation of ESCs into embryoid bodies (EBs) in vitro leads to a 2- to 
4-fold increase in MHC I expression. Prior to ESC use in clinics problems stemming 
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from their isolation, propagation and purification as well as their controversial immuno-
neutrality and tumorigenic potential need to be addressed. ESCs are also associated with 
prominent ethical concerns.  
 
Figure 17: Potential of embryonic stem cells for regenerative medicine. Picture adopted 
from [13]. 
Human perinatal extra-embryonic mesenchymal stem cells 
Within the last decade, perinatal extra-embryonic tissue-derived stem cells were 
considered a viable cell source for regenerative medicine [102, 103]. These cells, of 
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mesenchymal phenotype, are obtained during gestation from amniotic fluid or after 
termination of gestation from aborted material. Additionally, human perinatal cells can 
be isolated immediately after delivery from extra-embryonic tissues like foetal 
membranes, placentas, umbilical cords, amniotic fluid, and human umbilical cord 
blood. As, extra-embryonic tissues are normally discarded after birth, the isolation of 
these cells is free of the ethical concerns that incarcerate other stem cell types [102]. 
Human extra-embryonic mesenchymal stem cells (EE-MSCs) can be of foetal or 
maternal origin. Depending on that they exhibit a slightly variable phenotypic profile 
[104-106]. Currently, foetal EE-MSCs are considered to be stem cells with features that 
combine the pluripotent properties of ESCs and multipotent properties of adult 
mesenchymal stromal cells (MSCs) [Figure 18].  
 
 
 
Figure 18: Ontogenetic development stages of human perinatal mesenchymal stem cells. 
Picture adopted from [103]. 
Due to the close ontogenic relationship of embryonic stem cells with MSCs derived from 
extra-embryonic tissues, amniotic fluid, and umbilical cord blood, embryonic stem cells  
might have immunoprivileged characteristics, a broader multipotent plasticity, and a 
faster proliferation than adult MSCs [103]. Furthermore, unlike totipotent ESCs, 
multipotent EE-MSCs do not show any sign of teratoma formation after implantation in 
vivo. However, current experimental data characterizes EE-MSCs as a particularly 
interesting cell type for potential clinical utility and bio-banking, as their biomedical 
potential is only partially elucidated. 
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Human postnatal mesenchymal stem cells 
Almost all human postnatal tissues contain varying amounts of multipotent MSCs that 
reside in niches and normally differentiate into specific cell types of a given tissue. 
Postnatal stem cell types are largely of a mesenchymal phenotype and can be 
differentiated into multiple specialized lineages, such as adipogenic, chondrogenic, 
osteogenic or myogenic, for instance [Figure 19].  
 
 
Figure 19: Differentiation potential of adult mesenchymal stem cells. Picture adopted from 
[13]. 
Compared to human ESCs, human perinatal and postnatal MSCs possess a significantly 
reduced self-renewal and differentiation potential [107, 108]. It is challenging to 
characterize these cell types, as there is no unique marker that would allow their specific 
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prospective isolation. According to a minimal criteria for defining human MSCs, as 
proposed by the  International Society for Cell Therapy, human MSCs should at least be 
adherent to the tissue culture polystyrene (TCPS) and be differentiable towards 
adipogenic, chondrogenic, and osteogenic lineages. Additionally, they should possess 
specific phenotypes characterized by the expression of clusters of differentiation like 
CD73, CD90, and CD105, and the lack of expression of CD45, CD34, CD14, and HLA-
DR. Experimental analysis revealed that MSCs derived from different tissues exhibit 
slightly different surface marker expressions, indicating that these cells might have also 
slightly different features and capacities. Moreover, the proliferation and differentiation 
capacity of perinatal and postnatal MSCs can vary depending on tissue type, donor age, 
or foetal development stage, respectively. Contrary to previous assumptions, these cells 
are immunogenic. Their implantation is only possible in conjunction with 
immunosuppressive drug administration. 
Despite these hurdles, significant progress in using human adult MSCs has been 
demonstrated during the past two decades. So far, bone marrow transplantation is the 
most successful, clinically-approved method of cell therapy. Starting from early 1990‟s, 
adult MSCs have been used in the treatment of acute and chronic graft-versus-host 
disease (GVHD). Moreover, bone marrow transplants containing a mix of mesenchymal 
and hematopoietic stem cells are described to repopulate damaged, diseased or 
malignant cells with fresh cells, which can later be specifically instructed to differentiate 
into the appropriate tissue or blood cell types. It has been shown that allogenic bone 
marrow MSC transplants have potential in the treatment of leukaemia, myocardial 
infarction, pancreatic regeneration, neurological disorders, and inherent abnormalities, 
such as osteogenesis imperfecta [109]. An increasing number of scientific data as well as 
first successful results of clinical trials demonstrate that the therapeutic effects of MSCs 
might not be related to their differentiation capacity, but rather, to their immuno-
modulatory potential and the release of paracrine signals [110, 111]. Although promising, 
stem cell therapies using human MSCs are not yet established as routine clinical 
methods. The clinical translation of MSCs is still blocked by various obstacles. Most 
prevalent among them are the still unclear associations between phenotypic 
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characteristics and biological functions of MSCs, as well as a lack of data about long-
term safety, transplant actions in vivo, and transplant efficacy in the clinical setting. 
  
Challenges with the clinical use of stem cells 
Stem cells, in combinations with smart biomimetic materials, have been used to 
establish novel cell-based therapies and tissue-engineered products.  
Despite promising achievements, the critical issues hampering broad the clinical 
applications of such strategies need to be solved. Among them, the long term survival of 
transplanted stem cells in host tissue, homogeneity of stem cell populations, control of 
stem cell migration fate and function after transplantation, and the establishment of a 
treatment regimen for stem cell-replacement therapies are the most pressing of issues 
[Figure 20]. After developing new, clinically-relevant methods for the isolation and 
purification of stem cell populations, their propagation in clinically-relevant, serum- or 
xenogeneic-free environments and subsequent long-term freezing will be necessary in 
establishing functional non-immunogenic stem cells. Moreover, a better understanding 
of the epigenetic mechanisms participating in self-renewal and differentiation as well as 
in the immunogenic response of stem cells will be necessary for their effective clinical 
utilization. 
 
Figure 20: Obstacles on the way for broad clinical use of stem cells. Picture adopted from 
[13]. 
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1.12. BIOMATERIALS FOR TISSUE ENGINEERING 
An ideal biomaterial for in vitro drug testing, toxicological analysis, cell banking, and 
reconstruction of damaged or diseased human tissues in vivo should be non-
immunogenic, biocompatible, highly reproducible, approvable, and affordable. 
Moreover, such scaffolds should replicate features of native human tissue and allow for 
the fast regeneration of target tissue [112]. Biocompatibility is the most critical 
characteristic for the successful clinical use of a concrete biomaterial. According to 
Williams‟ 1987 definition, biocompatibility is the ability of a material to perform with an 
appropriate host response in a specific application. A biomedical material is considered 
to be biocompatible if it actively resists blood clotting and bacterial colonization. 
Furthermore, it should not aggravate the healing process. Unfortunately, though a broad 
range of biomaterials are used for biomedical applications [95], many induce a non-
specific, stereotyped biological reaction. 
Biomaterials can be divided into five major classes: polymers, metals, ceramics 
(including carbons, ceramics, and glasses) as well as plant- and animal-derived 
materials, and human tissue-derived scaffolds. All classes of biomaterials can be 
characterized by six parameters: type of bulk material, dimension of architecture and 
porosity, physico-chemical surface composition, mechanical properties, type of initial 
scaffold environment, and degradability [95, 113, 114]. Due to their versatility, 
biomaterials can play different roles. For cell-based implants biomaterials can serve as 
space holders. In such situations, they prevent incorporation of surrounding tissues into 
the body of implant or facilitate attachment, survival, migration, and controllable 
differentiation of stem cells. Moreover they can serve as clusters for vascularisation, 
formation, and remodelling of de novo generated tissue as well as vehicles for delivery of 
cells to the damaged tissue. They can also facilitate retention and distribution of specific 
cells throughout the injury cites [113, 114].   
 
Natural biomaterials 
Allogenic and xenogenic bone, skin, intestinal mucosa, and human foetal membranes, 
are tissues that have been employed for the generation of decellularized ECM. The 
human foetal membrane is one of the oldest scaffolds used in tissue engineering 
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applications. Due to its bacteriostatic, anti-angiogenic, anaesthetic, immunosuppressive 
properties, and its ability to inhibit scarring and promote wound healing, the human 
amniotic membrane can be considered as an ideal scaffold for surgery and wound 
healing management [115]. Currently, cryopreserved amniotic membranes (Cryo-AM) 
are widely used in surgical applications because of their clinical efficacy and safety [116]. 
Biopolymers represent the biggest class of materials used in medical applications. The 
development of polymeric biomaterials can be considered as an evolutionary process. 
Reports on the applications of natural polymers as biomaterials date back thousands of 
years [117]. They can be derived from natural components or manufactured from 
synthetic organic processes. Currently polymeric biomaterials are widely used for the  
production of orthopaedic, dental, soft-tissue, and cardiovascular substitutes and 
implants [95].  
Natural biopolymers are very similar or even identical with macromolecular substances 
of natural biological environment. Most of today‟s natural biopolymers are constituents 
of the ECM obtained from different animal tissues, such as tendons, muscles, cartilages, 
and skin. These biopolymers include collagen, glycosaminoglycans, gelatine, fibrin, 
heparin, and hyaluronic acid. Furthermore, natural biopolymers can be manufactured 
from such plant components as cellulose, sodium alginate, and natural rubber. Due to 
their inherent biological properties, natural biopolymers are non-toxic and do not 
provoke chronic inflammatory reaction. Furthermore, because of the similarity to 
naturally occurring components natural biopolymers are able to function on the 
molecular level. The greatest disadvantages of biological polymer scaffolds are batch-to-
batch variations and limited versatility for designing of exogenous ECM with specific 
well defined properties, immunogenicity, spontaneous degradation by natural enzymes, 
and pyrolytic decomposition by temperatures below the melting point [95]. 
 
Synthetic biomaterials 
Modern synthetic biopolymers range from hydrophobic, non-water-adsorbing 
materials, such as silicone rubber (SR) or polyethylene (PE), to hydrophilic materials, 
such as poly(vinyl chloride)  (PVC) or co-poly(lactic-glycolic acid) (PLGA). It can be 
water-swelling materials, such as poly(hydroxyethyl methacrylate) (PHEMA) or water 
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soluble materials, such as poly(ethylene glycol) (PEG) [95]. The application of such 
synthetic polymers to medicine is a recent phenomenon. The use of polymeric 
biomaterials as we know them today started in the 1940s during the second world war 
[118]. During the latter half of the twentieth century, material scientists attempted to 
engineer novel polymeric materials and modify existing polymers that could exhibit 
biocompatibility and adequate mechanical properties suitable for specific biomedical 
applications. In addition, recent advances in biotechnology and pharmaceutical science 
opened novel frontiers in biomedical fields, demanding materials with bioactivity, 
biocompatibility, and in many cases transient existence [119]. Such polymers can be 
produced in large quantities and with highly reproducible properties. The in vivo 
stability of biopolymers can be tuned by modulating their chemical composition. The 
greatest disadvantage associated with synthetic biopolymers is their inability to 
specifically interact with the biological system. However, the use of biologically inert 
materials (materials that neither present biological signals nor respond to proteolytic 
remodelling) served as starting point for the engineering novel materials. Such synthetic 
materials can be designed to overcome the limitations associated with naturally derived 
materials. In recent studies, materials with specific mechanical, chemical and biological 
properties have been synthesized. Now, fully-defined materials are available that can be 
used to replace naturally derived materials for the formation of tissue like constructs in 
vitro. Their usefulness has also been demonstrated in vivo. Today, these materials are 
mainly used to study cell-matrix interactions and the presentation of biologically active 
molecules for therapeutic approaches. More research is required to make such materials 
true alternatives for naturally-derived materials, which allow cellular remodelling and 
tissue regeneration [79, 120]. Nonetheless, synthetic biomaterials hold great promise in 
becoming the basis for the de novo generation of engineered tissues under well-defined 
conditions.  
1.13. NEW STRATEGIES FOR TISSUE ENGINEERING 
Novel tissue engineering strategies developed over the last decade include the use of 
smart stimuli-responsive materials such as intelligent hydrogels and polymers. Recent 
experimental results have shown that though such approaches are very profitable, 
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several critical conditions must be still considered  namely, stimuli-responsive materials 
must interact with proteins and cells without interfering with their biological activities, 
maintain their features after implantation, and be non-toxic and non-tumorigenic to 
surrounding cells and the microenvironment [121].   
  
Stimuli – responsive, “smart” materials 
From the tissue-engineering point of view, stimuli-responsive materials allow for the 
generation of 3D matrices, such as hydrogels and 2D coatings, assembled from 
polyelectrolyte multilayers, with the potential to control spatial organization, adhesion, 
migration, functionality, and integration of cells [Figure 21].  
 
 
Figure 21: Possible application of stimuli-responsive materials in regenerative medicine.  
Picture adopted from [121]. 
Major advantage of stimuli-responsive materials, compared to conventional biomaterial 
scaffolds, is their unique ability to regulate the spatial-temporal interactions at the 
cellular level [121]. 
“Smart” materials might respond to specific stimuli, such as temperature, pH, light, 
electric field, magnetic field, and so forth. Dependent on the physico-chemical 
composition of the material and kind of the stimulus, “smart” scaffolds can dramatically 
change in terms of shape, structure, solubility, adhesiveness, and transition, to name a 
few [122]. For example, “intelligent hydrogels” can exhibit swelling depending on 
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external environmental conditions. Moreover, the response of “smart” scaffolds on a 
specific stimulus can be tuned by changing of the micro-environmental properties. 
Current applications of stimuli-responsive “smart” materials include the engineering of 
tuneable scaffolds for controlled adhesion, propagation, spatial organization, or 
differentiation of cells, scaffolds for regulation of the bimolecular environment, 
functional self-assembled scaffolds, scaffolds for controlled and targeted drug delivery, 
and scaffolds enhancing tissue regeneration. A widely used example of such “smart” 
polymer is hydrogels, which collapse in water after the decrease of environmental 
temperature. Such thermo-responsible poly-N-iospropylacrylamide (PNIPAAm) 
coatings are also used for cell sheet engineering [95].  
 
Cell sheet engineering 
Cell sheet engineering is a new, versatile, and flexible scaffold-free method for the 
delivery of cells. This method is based on enzyme-free harvesting of contiguous viable 
cell monolayers from “smart” biomimetic coatings through the application of specific 
stimuli. Single cell sheets can either be applied directly or after assembly into three-
dimensional tissue-like structures consisting of multiple cell layers. By the choice of the 
cell source and the arrangement of cell sheet structures, heterotypical cell assemblies 
can mimic the in vivo arrangement. Currently, three different platforms for the 
detachment of contiguous cell sheet are applicable: temperature, magnetic field, and 
electrical charge [80]. The most prevalent approach among these three is cell sheet 
engineering on thermo-responsive poly-(N-iospropylacrylamide) (PNIPAAm) grafted 
culture dishes [Figure 22].  
Under normal culture conditions, the surface of such dishes is relative hydrophobic and 
cells attach, spread, and proliferate similarly to the normal tissue culture polystyrene. 
However, once the environmental temperature is reduced below the polymer‟s lower 
critical solution temperature (LCST), the surface will be converted to a hydrophilic one. 
This leads to the swelling of the coating and the formation of a hydrated layer between 
the dish and the attached cells [123]. This effect allows spontaneous detachment of cell 
sheets without the need for an enzymatic treatment, such as trypsinization or 
accutesation. 
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Cell sheet engineering that utilized thermo-sensitive PNIPAAm surfaces was introduced 
by Teruo Okano over a decade ago and has been successfully pre-clinically applied in the 
reconstruction of ocular surfaces, periodontal ligaments, oesophagus, cardiac muscle, 
bladders, and bones, as well as for treatment of diabetes mellitus [124-126]. Moreover, 
the cell sheets peeled from thermo-responsible polymer surfaces show promise for 
polysurgery, a method of repetitive transplantation for up to 30 multilayered cell-sheet 
grafts, allowing, for example, the generation of 1 mm-thick myocardial tissue-like 
structures [127].  
 
 
Figure 22: Cell sheet engineering on thermo-sensitive biomimetic surfaces. With typical 
proteolytic harvest by trypsinization, both ECM and cell-to-cell junction proteins are 
degraded for cell recovery (A). In contrast, cells harvested from temperature responsive 
dishes are recovered as intact sheets along with their deposited ECM, by simple 
temperature reduction (B). Picture modified from [123]. 
Transplantation of multi-layered “polysurgical” structures over arteries or veins has 
been shown to induce the formation of a vascular network that could be ectopically 
connected to the host vasculature [Figure 23].  
Additionally, currently performed studies demonstrated that 3D tissue-like constructs 
composed from stacked cell sheets can be pre-vascularized in vitro by incorporation of 
sparsely cultured human umbilical vein endothelial cells (HUVEC) [128, 129].  It has 
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been reported by Sasagawa et al. that after sandwiching of between two sheets of 
myoblastic cells inserted HUVEC started to sprout and form network structures [129]. 
Moreover, endothelial networks incorporated into the multiple structures composed 
from five sheets of myoblasts were observed to connect to the host vasculature after 
subcutaneous transplantation into the nude rats. In the second study performed by 
Asakawa et al. single mono-cultured EC sheets were sandwiched between two layers of 
normal human dermal fibroblasts (NHDF) in different orders. Pre-vascular networks 
formed by HUVEC were observed in all such triple-layer constructs [128].  
 
 
Figure 23: Principle of polysurgery approach. (a) Individual cardiomyocyte sheets are 
harvested from temperature-responsive culture dishes and stacked to create layered 
constructs. (b) Triple-layer myocardial grafts are transplanted subcutaneously. (c) After 
transplantation, neovascularization occurs within the bioengineered tissues. (d) After 
sufficient neovascularization has occurred, a second triple-layer myocardial graft is 
transplanted directly over the first construct. (e) Neovascularization of the second graft 
occurs through the first construct, creating thick tissues that can overcome the limits of 
passive diffusion. Picture adopted from [127]. 
 
Cell sheet engineering on polyelectrolyte multilayer coatings  
Cell sheet engineering on polyelectrolyte multilayer coatings, i.e. PEM-based cell sheet 
engineering, presents an alternative approach to the aforementioned issues.  
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Polyelectrolyte multilayer hydrogels (PEM), first introduced in 1992, represent a specific 
type of “smart” 2D coating generated by self-assembly. PEM self-assembly is a 
repetitive, alternating, layer-by-layer adsorption of cationic and anionic polyelectrolytes 
from dilute aqueous solutions. Their deposition is a significant and versatile means of 
modifying biomaterial surfaces [130].  
The preparation of PEMs is simple and widely applicable. The electrostatic interaction 
between the oppositely charged polyelectrolytes drives the build-up of multilayers, 
which occurs upon dipping material into polymer solution or spraying of polymer 
solution on the material. The PEM modification can be done with materials of any size, 
shape, or texture. The method allows the build-up of coatings from several nanometre to 
even micrometre thickness that exhibit a long-range order and stability, whereas the 
layers are highly interpenetrated at short range [131, 132]. Generally, PEM coatings can 
be engineered for specific bio-affinities and deposited in a high spatial order [133]. 
Applications of PEMs currently include bio-sensing in microarrays, cell encapsulation, 
and serving as carrier systems for bioactive agent delivery. 
Classical strategies have assured continuous progress in tissue engineering during the 
last two decades, shown necessary relevance for clinical applications, and been used 
successfully in patient care in some instances [64]. However, routine clinical 
applications of tissue engineering products are hampered by the absence of preformed 
vascularization, immunological rejection, high risk of infections, and malignancy [113, 
134]. These factors play a critical role in tissue integration, cell necrosis, and implant 
rejection. Additionally, the “scale-up” of classical tissue engineering strategies might be 
limited by restricted availability and high costs of biological materials [135]. Failure of 
engineered tissue substitutes are induced by immunological rejection, cell necrosis, 
inflammation or associated postoperative infections and can lead to chronic 
inflammation, invalidity, or even death, and thus reduces the potential of the tissue 
engineering approach [96, 136]. For this reason, novel strategies, fashioned during last 
decade, aim to generate tissue substitutes in the absence of biomaterials. Scaffold-free 
tissue engineering and tissue engineering using stimuli-responsive scaffolds are 
prominent examples of such efforts. Scaffold-free constructs consist of different cell 
types that, by self-arrangement, form tissue-like assemblies. The controlled patterning 
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of cells and the formation of vascular structures inside cell masses, which go much 
beyond the limits of oxygen diffusion and the transport of nutrition and waste products, 
would be a critical step towards the formation of more functionally-engineered tissues 
and their efficient connection to host vascularisation systems. 
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CHAPTER 2 
SCOPE 
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Correct development, as well as following engraftment and survival of complex tissue-
like substitutes generated de novo, are among the most critical aspects of modern 
regenerative medicine and perhaps the most ambitious aim of tissue engineering.  
In the context of my thesis a polyelectrolyte multilayer (PEM) based methodology is 
developed for engineering and harvesting of human extra-embryonic perinatal 
mesenchymal stem cell sheets. This new technology provides an alternative for the 
platform based on thermo-responsive polymers. The combination of the unique 
regenerative potential of perinatal MSCs with advantageous properties of cell sheet 
engineering will allow designing of biocompatible, cost effective tissue-like substitutes 
for regenerative medicine. The basis of my thesis is a new method that allows for the 
harvesting of intact cell sheets by electrochemical means. In combination with micro-
patterning techniques this method also allows for the control of the spatial organization 
of cells in two dimensions.  
First results section (Chapter 4) describes the protocols and critical parameters for 
routine and effective isolation, long-term cultivation, and maintenance of human term 
placenta-derived mesenchymal stem cells (PD-MSCs). In order to evaluate their 
regenerative potential, isolated human PD-MSCs were systematically characterized in 
terms of: phenotype, genotype, growth and mortality rates, as well as mesodermal 
plasticity.  
The next results section (Chapter 5) contains the design of the functional polyelectrolyte 
multilayer (PEM) based platform for assembling of cell sheets from human PD-MSCs 
and the systematic characterization of the resulting PD-MSC sheets in terms of their 
regenerative potential. 
 The final results section (Chapter 6) is summarising optimal conditions for the non-
invasive peeling of intact PD-MSC sheets by electrochemical means. In addition, this 
chapter also contains the characterization of the electrochemically peeled PD-MSC 
sheets in terms of: viability, adhesion capacity, and mesodermal plasticity. As the 
evaluation of the viability, the in-growth, and the regenerative potentials of PD-MSC 
sheets after implantation is also very important for the final application this chapter 
finishes with experiments dealing with the instructed differentiation by co-culture with 
adult human osteoblasts. Such co-cultures can simulate the effect of stem cell sheet – 
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host tissue contact ex vivo and thus clarify whether the PD-MSC sheets indeed have 
potential for tissue regeneration.   
Overall I believe that the results of my thesis lead towards a principally new, very 
effective and practical method for the creation of three-dimensionally designed complex 
tissues for transplantation surgery, drug screening procedures and cell based therapy. 
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CHAPTER 3 
MATERIALS AND METHODS  
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3.1. ISOLATION OF HUMAN PLACENTAL MSCs 
 
In the first part of the chapter I am describing the materials and methods, which have 
been used for the isolation, characterization, and long-term cultivation of placenta-
derived mesenchymal stem cells (PD-MSCs).  
 
3.1.1. Placenta collection 
The Ethical Committee of the District of Zurich approved the protocol (study 
Stv22/2006). Following written consent, placentas, umbilical cords, uterus muscle 
biopsies, and umbilical cord blood samples were collected immediately after elective 
caesarean section in the absence of labour, preterm rupture of membranes, 
chorioamnionitis, or chromosomal abnormalities. Mean maternal age was 32 years 
(between 28 and 39 years) and mean gestational age was 38 ±1 weeks. Mean placental 
weight was 573 ±113 g.  
Isolation procedure is depicted on the [Figure 24]. After removal of decidua and foetal 
membranes, approximately 30g placental tissue was minced and washed three times in 
physiological saline. Blood vessels and clots were removed mechanically. The minced 
placental tissue was subjected to sequential digests with trypsin and collagenase I. First, 
to remove the trophoblastic epithelial cell layer, tissue was incubated in 50mL 0.25% 
trypsin solution containing 80U/mL DNase I (Roche AG, Basel, Switzerland) for 1 h at 
37°C. The remaining placental fragments were separated in a 250µm metal sieve from 
the 'trypsin cell suspension'. Approximately 15g of placental fragments were subjected to 
a second digest with collagenase. For that, tissue fragments were incubated with 50mL 
of 12.5U/mL collagenase I (Sigma-Aldrich AG, Buchs, Switzerland), 80U/mL DNase I 
for one hour at 37°C. Cell suspensions from both trypsin and collagen digests were 
filtered twice through 100µm cell strainers (BD Bioscience, San Jose, CA), then the cells 
were collected by centrifugation for 5min at 300 g. The cell pellets were shortly re-
suspended in hypotonic red blood cell lysis buffer (physiological saline with 2mm EDTA, 
0.5% BSA, without Ca und Mg, diluted 1:10 with distilled water), pelleted again by 5min 
centrifugation at 300g. Finally, the cells were suspended in 10ml Non Hematopoietic 
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Stem Cell Expansion Medium (NH expansion medium; Miltenyi Biotec GmbH, 
Bergisch-Gladbach, Germany) and plated into a single 75cm2 tissue culture flask (TPP 
AG, Trasadingen, Switzerland) and cultured at 37°C.  
 
 
 
Figure 24: Fractionation scheme for isolation of MSCs from term human placental tissue 
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3.1.2. Propagation of PD-MSCs in vitro 
Colony assay 
Freshly isolated PD-MSCs, passage 0, were plated at low density, i.e. 50 cells per well of 
6-well plates (TPP), and cultured at 37˚C, 5% CO2 in Non-Hematopoietic Stem Cell 
Expansion Medium (NH expansion medium). Outgrowing colonies of spread cells were 
visualized and counted by fluorescence microscopy using rhodamine-labelled phalloidin 
to stain actin cytoskeleton (Invitrogen, Basel, Switzerland), and 4‟6-diamidino-2-
phenylindole dihydrochloride (DAPI; Molecular Probes, Eugene, OR) to stain cell 
nuclei. Images were acquired with a Zeiss Axiovert 200M (Carl Zeiss AG, Feldbach, 
Switzerland) equipped with a digital camera AxioCam MRc, (Carl Zeiss AG, Feldbach, 
Switzerland).  
 
Growth kinetics 
PD-MSCs of passages 1, 10, and 20 taken from four different cases were plated at 5 x 103 
cells per well in 12 well-plates (TPP) and cultured at 37˚C and 5% CO2 in Non-
Hematopoietic Stem Cell Expansion Medium (NH expansion medium). All experiments 
were performed in triplicate. Cell counts were determined after 24, 48, and 72h culture. 
For that, cells were detached with 0.25% trypsin solution (GIBCO-Invitrogen AG, Basel, 
Switzerland) and counted with a Coulter Z1 cell counter (Instrumenten Gesellschaft AG, 
Zurich, Switzerland). Dead cells were identified by staining with 0.4% trypan blue 
staining solution (Sigma - Aldrich AG).  
 
3.1.3. Phenotypical analysis  
Flowcytometry 
Cells were collected by trypsinization. Reaction was performed on live cells, using 105 
cells per antibody reaction. Cells were incubated for 25 min with specific antibodies at 
4°C. Unstained, non-incubated cells serve as controls. Cells were fixed in 4% buffered 
formalin and analysed with a flow cytometer (FACSCalibur, Becton Dickinson, Franklin 
Lakes, NJ). A minimum of 104 gated events, were acquired for each sample. For staining 
of the intracellular markers CK-7, α-SMA, and vWF, cells were fixed in 4% buffered 
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formalin, shortly permeabilized by 10 min incubation in 0.9% saponin solution, and 
then incubated with specific antibodies for 25 min at 4°C. 
Information about primary and secondary antibodies used for flow cytometry and 
immunochemistry is provided separately [Table 1].  
 
ANTIGEN CLONE CONJUGATE HOST COMPANY
CD11b ICRF44 PE Mouse Biolegened
CD14 H5E2 - Mouse Biolegend
CD19 HIB19 PE Mouse Biolegened
CD34 AC136 FITC Mouse Miltenyi Biotec GmbH
CD44 G44-26 FITC Mouse BD Pharmingen
CD45 5B1. FITC Mouse Miltenyi Biotec GmbH
CD54 HA58 PE Mouse BD Pharmingen
CD73 AD2 PE Mouse BD Pharmingen
CD79a HM47 PE Mouse Biolegend
CD90* 5E10 - Mouse BD Pharmingen
CD105* 266 - Mouse BD Pharmingen
CD117 YB5.B8 PE Mouse BD Pharmingen
CD133/1 AC133 APC Mouse Miltenyi Biotec GmbH
CD163 GHI/61 PE Mouse BD Pharmingen
CD166 3A6 PE Mouse BD Pharmingen
CD271 ME20.4-1H4 PE Mouse Myltenyi Biotec GmbH
HLA-ABC G46-2.6 FITC Mouse BD Pharmingen
HLA-DR G46-6 FITC Mouse BD Pharmingen
Cytokeratin-7 CAM 5.2 FITC Mouse BD Pharmingen
Cytokeratin-18 CY-90 FITC Mouse Sigma-Aldrich AG
Alpha Smooth Muscle Actin 1A4 PE Mouse R&D Systems
Von Willebrandt Factor Sheep Polyclon FITC Sheep Abcam plc
KDR / VEGF receptor 2 89106 PE Mouse R&D Systems
PlAP H17E2 - Mouse AbD Serotec
Hepatocyte specific antigen OCH1E5 - Mouse Abcam plc
SSeA-3 MC-631 - Rat R&D Systems
SSeA-4 MC813-70 PE Mouse R&D Systems
Oct-3/4 240408 - Rat R&D Systems
Vimentin V9 PE Mouse Sigma-Aldrich AG
Nestin 10C2 - Mouse Abcam plc
E-Cadherin 36 PE Mouse BD Pharmingen
ESCM Tra-1-60* Tra-1-60 - Mouse Abcam plc
ESCM Tra-1-81* Tra-1-60 - Mouse Abcam plc
ZO-1 ZO-1-1A12 FITC Mouse Zymed Laboratories
 
 
Table 1: Antibodies used for flow cytometry and immunocytochemistry 
  
Immunocytochemistry 
Briefly, cells on 15 mm glass cover slips (Menzel GmbH + Co KG, Germany) were fixed 
for 5 min in 100% acetone, then rehydrated in PBS and blocked with Ultra V Blocking 
buffer (Bio Vision Corporation, England). For staining for intracellular proteins, cells 
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were permeabilized with 0.1% Triton X-100 for 3min, then incubated with primary 
antibodies for 1h at room temperature. In case of using unconjugated primary 
antibodies, samples were subsequently incubated with secondary polyclonal FITC 
conjugated goat anti-mouse Ig (BD Pharmingen, Switzerland) or FITC-conjugated 
rabbit anti-rat Ig antibodies (Dako Cytomation, Glostrup, Denmark) for 30min at room 
temperature. All cell samples were additionally counterstained with DAPI. Images were 
taken with a Zeiss Axiovert 200M (Carl Zeiss AG) equipped with a digital camera 
AxioCam MRc, (Carl Zeiss AG) and analysed with AxioVs40 V 4.5.0.0 imaging software 
(Carl Zeiss AG). 
 
3.1.4. Cytogenetic analysis 
Chromosome analysis 
Chromosome analysis of PD-MSCs cultures, passage 3, from six donors was performed. 
Briefly, metaphase chromosome preparations were performed according to standard 
procedures at a 400-500 GTG band level. Analysis and identification of the 
chromosomes was performed using a Zeiss Axioplan microscope (Carl Zeiss AG, 
Feldbach, Switzerland). Images were recorded with a Photometrics CCD KAF1400 
camera (Photometrics, Tucson, AZ) and controlled with smart capture imaging software 
(Vysis, Inc., Downers Grove, IL). 
 
FISH analysis for detection of sex determination region 
Fluorescence in situ hybridisation (FISH) studies for detection of sex determination 
region (SRY) were performed using chromosome X (Xp11.1-q11.1, locus DXZ1) and 
chromosome Y (Yp11.1-q11.1, locus DYZ3, alpha satellite) probes Vysis (Abbott 
Molecular Inc., IL) according to the manufacturer‟s instructions (Abbot Molecular Inc., 
Des Planes, IL 60018). Analysis of at least 200 metaphases and interphases was 
performed on PD-MSCs isolated from three male deliveries at passage 3 using a Zeiss 
Axioplan epifluorescence microscope (Carl Zeiss AG). Images were recorded by 
Photometrics CCD KAF1400 camera (Photometrics) and controlled with smart capture 
imaging software (Vysis, Inc.) 
63 
   
3.1.5. Multipotent differentiation assay 
Cultures of PD-MSCs at passage 6 taking from three random donors were tested for 
differentiation towards mesodermal lineage in vitro. Differentiation was induced by 
their culture in commercial differentiation media: AdipoDiff, ChondroDiff, and 
OsteoDiff Induction Media (Miltenyi Biotec GmbH) following the manufacturer's 
protocol. Control cultures were grown in NH expansion medium (Miltenyi Biotec 
GmbH). After differentiation, cells were examined microscopically with a Zeiss Axiovert 
200M (Carl Zeiss AG). 
 
Adipogenic differentiation 
For adipogenic differentiation, PD-MSCs were cultured at 50 x 103 cells per well of 12 
well-plates in AdipoDiff induction medium (Miltenyi Biotec GmBH) for 3 weeks, with 
fresh media added every 48h. Oil Red O was utilized to visualize fat droplets. Briefly, 
cells were washed twice with PBS, fixed in pre-cooled methanol for 5 min, rinsed with 
deionised water, and then incubated with 0.5% Oil Red O (Sigma-Aldrich AG) in 
isopropanol for 20 min at room temperature. Finally, stained cells were washed with 
water and analysed microscopically.  
 
Chondrogenic differentiation 
Chondrogenic differentiation was performed under micromass conditions in 
ChondroDiff induction medium (Miltenyi Biotec GmbH), according to the 
manufacturer's instructions. Briefly, 5 x 106 MSCs were pelleted by 5 min centrifugation 
at 300g in a cell culture centrifuge. The micromass was kept in ChondroDiff medium for 
24 days, with fresh media added every 48 h. The pellets were fixed in 10% formalin, and 
then finally embedded in paraffin. Staining for proteoglycans was performed on 
deparaffinised 5 μm sections by 30 min incubation with 3% Alcian Blue (Sigma-Aldrich 
AG) in 3% acetic acid, pH 2.5. Counter stain was performed with Nuclear Fast Red 
(DAKO Cytomation). 
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Osteogenic differentiation 
For osteogenic differentiation, 3 x 104 PD-MSCs were seeded in 12 well plates (TPP) and 
maintained in OsteoDiff induction medium (Miltenyi Biotec GmbH) for 3 weeks, with 
fresh medium added every 48h. After 21 days, cells were fixed in 70% ethanol. 
Extracellular calcium deposition was stained by 45 min incubation with 2% Alizarin Red 
S (Sigma-Aldrich AG) in water. Finally, stained cells were washed with deionised water 
and analysed microscopically. 
 
Angiogenic differentiation 
Angiogenic differentiation was performed as described [137]. Briefly, PD-MSCs were 
seeded at the density of 2.5 x 104 cells per well of 12 well plates and cultured for 7 days in 
Dulbecco's Modified Eagle Medium (Invitrogen AG) supplemented with 2% foetal 
bovine serum (Invitrogen AG) and 50 ng/ml vascular endothelial growth factor 121 (29). 
Control cultures were performed without VEGF. After 7 days, cells were fixed and 
stained with mouse anti-human CD34 antibodies (Miltenyi Biotec GmbH). 
 
Statistical analysis 
Data are shown as mean ± SD. Mann-Whitney (nonparametric) test was performed 
using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA). 
Data are given as mean ± standard deviation. Significance level was set at p < 0.05. 
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3.2. DESIGNING OF POLYELECTROLYTE MULTILAYER SUBSTRATES 
 
In the second part of the chapter I am describing materials and methods which were 
used for the fabrication, mechanical characterisation, and tuning of the polyelectrolyte 
multilayer coatings (PEM) 
  
3.2.1. Preparation of polyelectrolyte multilayer substrates 
 
Substrate cleaning 
Pre-treatment of silicate glass coverslips (for cell culture experiments) or silicate 
waveguides slides (for optical measurements) was done as previously described [138]. 
 
Polyelectrolyte and fibronectin solutions 
Solutions of poly(L-lysine) hydro-bromide (PLL, Mw 15-30 kDa) (Sigma, AG, 
Switzerland) and hyaluronic acid sodium salt from bovine vitreous humour (HA, Mw 
300 kDa) (Sigma, AG, Switzerland) were prepared at 1mg/ml in HEPES-2 buffer (10 
mM 4-(2- hydroxyethyl)piperazine-1-ethanesulfonic acid, pH 7.4, 0.15M sodium 
chloride) [139]. Solutions of poly(allylamine hydrochloride) (PAH, Mw 70 kDa) (Sigma, 
AG, Switzerland) and poly(styrene sulfonate) (PSS, Mw 70 kDa) (Sigma, AG, 
Switzerland) were prepared at 0.1mg/ml in HEPES-2 buffer at pH 7.4 [140]. Human 
recombinant fibronectin (FN) (Biomedical Technologies Inc., USA), was used at 50 
µg/ml in HEPES-2 buffer. All solutions were sterile filtered through 0.22 μm filters 
before use. Fluorescent labelling of FN was performed with Alexa Fluor® 488 protein 
labelling kit (Invitrogen, Switzerland) following the manufacturer's protocol. 
 
Preparation of native [PLL/HA] multilayer substrates 
Native “soft” (PLL/HA)i multilayer coatings, where i is the number of layer pairs, were 
prepared on indium tin oxide (ITO) coated silicate glass slides with dimensions of 1x2 
cm. Sequential layering of the polyelectrolytes and rinsing were done using robotized 
system Mindstorms (LEGO GmbH, Germany). First layer was adsorbed by 5 sec 
spraying of the PLL solution on ITO coated silicate glass slide. Then after 15 sec. pause 
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the PLL solution was rinsed by spraying of HEPES-2 buffer for 5 sec. Then HA was 
adsorbed and subsequently rinsed following the same procedure. Adsorption of PLL and 
HA was performed alternately until the desired multilayer was built. In some 
experiments, an additional layer of FN was adsorbed by immersion for 45 minutes. The 
multilayers were kept in 0.9% NaCl physiological solution (B-Braun AG, Germany). 
 
Preparation of cross-linked [PLL/HA] multilayer substrates 
Cross-linked “semi-soft” (PLL/HA)i multilayer coatings, where i is the number of layer 
pairs, were prepared on indium tin oxide (ITO) coated silicate glass slides with 
dimensions of 1 x 2 cm.  
Sequential layering of the polyelectrolytes and rinsing were done using robotized system 
Mindstorms (LEGO GmbH, Germany). First layer was adsorbed by 5 sec spraying of the 
PLL solution on ITO coated silicate glass slide. Then after 15 sec. pause the PLL solution 
was rinsed by spraying of HEPES-2 buffer for 5 sec. Then HA was adsorbed and 
subsequently rinsed following the same procedure. Adsorption of PLL and HA was 
performed alternately until the desired multilayer was built.  
In some experiments, an additional layer of FN was adsorbed by immersion for 45 
minutes.  
Cross-linking of multilayers was performed with N-(3-dimethylaminopropyl-N‟- 
ethylcarbodiimide hydrochloride (EDC) in combination with N-
hydroxysulfosuccinimide sodium salt (NHS) similar as described by Richert et al [139]. 
The coupling chemistry is based on the reaction between activated carboxylate groups of 
HA and the ammonium groups of PLL and results in the formation of amide bonds. 
EDC and NHS were prepared in 0.9% NaCl in deionised water and mixed together 
immediately before use. The various EDC concentrations tested were 0, 8, 40, 80, and 
800 mM; the NHS concentration was in all reactions 200 mM. The pH of mixed cross-
linker solution was determined as 5.5. The multilayers were incubated in EDC/NHS for 
12h at 4°C. Then the EDC/NHS solution was removed and the multilayers were rinsed 
three times with 0.9% NaCl physiological solution (1 x 1h, 1x 1h, 1 x 3h) to hydrolyse 
unreacted cross-linkers. 
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Preparation of [PAH-PSS] multilayer substrates 
Synthetic “stiff” (PAH/PSS)i multilayer coatings, where i is the number of layer pairs, 
were prepared on indium tin oxide (ITO) coated silicate glass slides with dimensions of 
1x2 cm. Sequential layering of the polyelectrolytes and rinsing were done using 
robotized system Mindstorms (LEGO GmbH, Germany). First layer was adsorbed by 5 
sec spraying of the PAH solution on ITO coated silicate glass slide. Then after 15 sec. 
pause the PAH solution was rinsed by spraying of HEPES-2 buffer for 5 sec. Then PSS 
was adsorbed and subsequently rinsed following the same procedure. Adsorption of 
PAH and PSS was performed alternately until the desired multilayer was built. In some 
experiments, an additional layer of FN was adsorbed by immersion for 45 minutes. The 
multilayers were kept in 0.9% NaCl physiological solution (B-Braun AG, Germany). 
 
Validation of polyelectrolyte multilayer build-up by (OWLS) 
Deposition of polycations, polyanions and fibronectin on waveguides was measured in 
situ by OWLS as described by us and others previously [131, 138]. The instrument and 
the waveguides were obtained from (Micro Vacuum Ltd., Budapest, Hungary). The 
waveguide was mounted into a flow through cell with a volume of 15 μL and left in 
HEPES-2 buffer overnight. After stabilization of the buffer baseline, polyelectrolyte 
solution was injected and let adsorbed for 5 min for PLL and HA, with 2 min rinsing 
steps in between. Adsorption of PLL and HA layers was performed alternately until the 
desired number of layers was built. In some experiments, an outer layer of FN was 
injected and let adsorbed for 120 min. 
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3.3. CELL SHEETS ON PEM SUBSTRATES: GROWTH AND CHARACTERIZATION 
 
In the third part of the chapter I am describing materials and methods which were 
used for the assembling of PD-MSC sheets on the PEM coatings and their following 
characterization. 
 
3.3.1. Cell attachment experiments 
Cell attachment experiments were performed on PEM-coated, 1x2 cm silicate glass 
slides. AT-MSCs, PD-MSCs, and MBs were seeded at various cell densities 0.5 x 106 
cells/cm2, and cultured in non-hematopoietic stem cell culture medium (Miltenyi 
Biotec, Germany). Control cultures were grown on tissue culture plastic. For analysis of 
cell spreading, cytoskeleton was stained with rhodamine-labelled phalloidin according 
to the manufacturer's instructions (Invitrogen, Switzerland). Cell nuclei were stained 
with 4‟6- diamidino-2-phenylindole dihydrochloride (DAPI; Molecular Probes, Eugene, 
OR). Images were acquired with a DMIL fluorescence microscope (Leica) equipped with 
a DML digital camera (Leica) at the 10x, 20x or 40x magnification. Cell densities were 
quantified calorimetrically using crystal violet staining. For that, slides were fixed in 
methanol for 20 min, then transferred into new 12-well plates, and incubated with 0.5% 
crystal violet (AppliChem GmbH, Darmstadt, Germany) in 20% methanol for 1h at room 
temperature, then rinsed with water and air-dried. Destaining was performed by 
overnight incubation in 2% SDS. Optical density of the extracts was determined at 600 
nm. In some experiments, cell counts were obtained from fluorescence micrographs of 
DAPI-stained cells using automated image analysis software Image J 1.34s (National 
Institute of Health, Bethesda, ML). 
 
3.3.2. Phenotypical characterization of MSC sheets 
To analyse their phonotypical profile, PD-MSC sheets were grown for 4 hours under 
standard cell culture conditions. After complete removal of the culture medium, cell 
sheets were washed once with PBS, and then dissociated by incubation with 0.25% 
Trypsin-EDTA solution (Invitrogen, Switzerland) at 37ºC and 5%CO2 for 5 min. For 
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FACS analysis 105 living cells per probe were prepared in custom made FACS buffer 
composed of PBS mixed with 1% of BSA. The cells were then incubated for 25 min at 4°C 
with fluorescently labelled primary antibodies HLA-ABC (BD Pharmingen, 
Switzerland), HLA-DR (BD Pharmingen, Switzerland), CD34 (Miltenyi Biotec GmbH, 
Germany), CD45 (Miltenyi Biotec GmbH, Germany), CD73 (BD Pharmingen, 
Switzerland), and unlabelled primary antibodies CD14 (BD Pharmingen, Switzerland), 
CD90 (BD Pharmingen, Switzerland), and CD105 (BD Pharmingen, Switzerland). 
Probes incubated with unlabelled primary antibodies were then additionally stained by 
incubation for 25 min at 4°C with a FITC labelled goat anti-human secondary antibody 
(BD Pharmingen, Switzerland). Unstained cells serve as negative controls. After staining 
all probes were washed with FACS buffer, fixed in 4% buffered formalin, and analysed 
with a flow cytometer (FACSCalibur, Becton Dickinson, Franklin Lakes, NJ). A 
minimum of 104 gated events, were acquired for each sample. 
 
3.3.3. Induced MSC differentiation on PEM substrates 
Mesodermal plasticity of PD-MSC sheets was analysed by their induction with 
commercially available differentiation media, according the manufacture protocols 
(MACS guide). Precisely, PD-MSC cultures of passage 6 were plated either onto 
fibronectin-terminated, cross-linked (PLL/HA)9-PLL or native (PAH/PSS)9 multilayers, 
deposited on ITO coated glass electrodes, at density 5 x 104 cells per cm2. 
 
Adipogenic differentiation 
Adipogenic differentiation of PD-MSC sheets was conducted for 21 days. At day 21 
induction medium was removed and cell sheets were fixed in ice-cold 100% methanol 
for 5 min at -20ºC. After that cell sheets were washed once with deionised water lipid 
droplets were visualized by staining with 0.5% solution of Oil Red O (Sigma-Aldrich 
GmbH, Switzerland) for 20 min at RT. Finally, stained cell sheets were washed three 
times with water and analysed microscopically. 
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Chondrogenic differentiation 
Chondrogenic differentiation was initiated for 21 days. At day 21 induction medium was 
removed and cell sheets were fixed in 4% paraformaldehyde for 20 min at RT. After that 
cell sheets were washed once with PBS and collagen II expression was demonstrated by 
immunocytochemical staining with polyclonal goat anti-human collagen II antibodies 
(Santa Cruz, Ltd. USA) and secondary FITC-conjugated anti goat antibodies (DAKO 
Cytomation, Denmark). Cell nuclei were stained with 4‟6- diamidino-2-phenylindole 
dihydrochloride (DAPI; Molecular Probes, Eugene, OR). Finally, stained cell sheets were 
washed three times with PBS and analysed microscopically. 
 
Osteogenic differentiation 
Osteogenic differentiation was initiated for 11 days. At day 11 induction medium was 
removed and cells were fixed in 70% ethanol for 40 minutes at RT. After that cell sheets 
were washed once with deionized water (B-Braun, Germany) and alkaline phosphatase 
expression was visualized by cytochemical staining with FAST BCIP/NBT (5-Bromo-
4cloro-3-indolyl phosphate/Nitro Blue Tetrazolium) (Sigma-Aldrich GmbH, 
Switzerland). Finally, stained cell sheets were washed three times with water and 
analysed microscopically. 
 
Confocal microscopy and image analysis 
Confocal images were acquired using Leica TCS-SP2 confocal microscope. The data 
were further processed using Imaris software v. 2.6 (Bitplane Scientific Solutions AG, 
Switzerland). 
 
Immunocytochemistry 
For immunofluorescent staining, PD-MSCs or C2C12 cells were plated at density of 1.5 x 
103 cells/cm2 on native or cross-linked FN-terminated [PLL/HA]9 coatings, then 
cultured for 24h. Then cells were permeabilized with 0.1% Triton X-100, and stained for 
vinculin using fluorescein isothiocyanate (FITC)-conjugated anti-vinculin antibodies 
(1:100; Sigma-Aldrich Chemie GmbH, Switzerland); cell nuclei were stained with DAPI. 
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Statistical analysis 
Data are shown as mean ± SD. Two-tailed unpaired t test was performed using Graph 
Pad Prism version 4.00 for Windows (Graph Pad Software, San Diego, CA, USA). 
Significance level was set at p < 0.05. 
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3.4. CONTROLLED PEELING OF MSC SHEETS FROM PEM SUBSTRATES 
 
In the fourth part of the chapter I am describing materials and methods which were 
used for the electrochemically and pH mediated peeling of the PD-MSC sheets as well 
as for the characterization of peeled PD-MSC sheets.  
 
Spontaneously peeling 
Cells were plated out at density of 1 x 106 cells/cm2 on “stiff” [PAH-PSS]9  coating and 
cultured for 12 h. After reaching confluence spontaneously peeling of cell sheets was 
started and they were mechanically removed from the PEM coating using tweezers. 
Resulting cell sheets were then analysed for the viability using live-dead staining. 
Additionally, peeled cell sheets were plated out in fibronectin coated six well plates and 
differentiated towards osteogenesis, chondrogenesis, and adipogenesis using standard 
differentiation conditions has been described before.    
  
PH mediated peeling 
For pH mediated cell sheet peeling NH expansion media with pH = 4, 5, 6, and 7 have 
been prepared. The pH adjustment was done using 1M NaOH and 6M HCl, respectively. 
After adjustment, pH was controlled using Seven Easy pH measure machine (Mettler 
Toledo GmbH, Switzerland). Cells were plated out at density of 0.5 x 106 cells/cm2 on 
“stiff” [PAH-PSS]9  coating and cultured for 12 h. After that, NH expansion medium has 
been removed and confluent cell sheets were washed once with 1 x PBS. NH expansion 
medium with different adjusted pH has been applied to the [PAH-PSS]9 coated ITO 
silicate glass surfaces for 15 min at RT.  Peeled at pH = 4 cell sheets have been analysed 
for vitality using live-dead staining procedure as described before.    
  
Peeling mediated by electrochemical means 
For electrochemically-induced cell sheet detachment, PD-MSCs were cultured for 4 
hours on (PAH/PSS)9 -coated ITO glass chips. The chips were then mounted in a custom 
made electrochemical flowcell provided with a similar three-electrode configuration  
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system as described before. Non-hematopoietic stem cell expansion media (Miltenyi 
Biotec GmbH, Germany) was supplemented with 3 mM HEPES. A current at density 30 
µA/cm² was applied using an AMEL potentiostat/galvanostat (model 2053, AMEL 
electrochemistry, Italy) and the samples were observed by phase contrast microscopy 
(DM IL, Leica Microsystems Ltd, Switzerland) until complete cell sheet detachment. 
 
Live-dead staining of harvested stem cell sheets 
Harvested PD-MSC sheets were analysed for vitality using live-dead staining procedure. 
For this cell sheets were rinsed three times with PBS and then incubated with a mixture 
of 1 µM calcein acetate and 2 µg/ml ethidium homodimer for 30 min. After rinsing three 
times with PBS, images were acquired using Zeiss Axiovert 200M (Carl Zeiss, 
Switzerland) equipped with a digital camera AxioCam MRc (Carl Zeiss, Switzerland), 
and finally analysed with AxioVision V. 4.5.0.0 software (Carl Zeiss, Switzerland). 
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3.5. INSTRUCTED DIFFERENTIATION OF MSC SHEETS AFTER PEELING 
 
In the fifth part of the chapter I am describing materials and methods which were used 
for the instructed differentiation of the electrochemically peeled PD-MSC sheets. 
 
Mesodermal differentiation of harvested stem cell sheets 
Peeled PD-MSC sheets were transferred to Petri dishes with diameter 35 mm (TPP, 
Switzerland) and allowed to adhere in non-hematopoietic stem cell expansion medium 
(Miltenyi Biotec GmbH, Germany) at 37ºC and 5% CO2 for 24 hours. After that culture 
medium was replaced with AdipoDiff, ChondroDiff, and OsteoDiff induction media 
(Miltenyi Biotec GmbH, Germany), respectively. Appropriate differentiation and 
staining procedures were performed according the manufacture protocols as described 
before. 
 
Co-culture of MSC sheets with osteoblasts – indirect contact 
Human osteoblasts (HOB) were plated out at density 0.5 x 106 cells/cm2 in the 12 
well/plate (TPP, Switzerland). Cells were grown to confluence in non-hematopoietic 
stem cell expansion medium (Miltenyi Biotec GmbH, Germany) at 37ºC and 5% CO2 At 
day 7 peeled PD-MSC sheets were transferred into the insert wells and co-cultured with 
HOB cultures for 14 days. In differentiation conditions PD-MSC sheets co-cultured with 
HOB cultures were additionally pre-stimulated with OsteoDiff medium (Miltenyi Biotec 
GmbH). In the co-culture control conditions PD-MSC sheets were co-cultured with PD-
MSC cultures and pre-stimulated with OsteoDiff medium. In the negative control 
conditions PD-MSC sheets were co-cultured with PD-MSC cultures without pre-
stimulation with OsteoDiff medium. At day 15 insert wells with cell sheets were removed 
and alkaline phosphatase expression was visualized by cytochemical staining with FAST 
BCIP/NBT (5-Bromo-4cloro-3-indolyl phosphate/Nitro Blue Tetrazolium) (Sigma-
Aldrich GmbH, Switzerland). Finally, stained cell sheets were washed three times with 
water and analysed microscopically. Additionally, collagen I expression was analysed 
using Real-Time PCR. 
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Co-culture of MSC sheets with osteoblasts – direct contact 
Human osteoblasts (HOB) were plated out at density 0.5 x 106 cells/cm2 in the 12 
well/plate (TPP, Switzerland). Cells were grown to confluence in non-hematopoietic 
stem cell expansion medium (Miltenyi Biotec GmbH, Germany) at 37ºC and 5% CO2 At 
day 7 peeled PD-MSC sheets were transferred direct on the layer of HOB cells and co-
cultured for 14 days as described above.  At day 15 PD-MSC sheets were removed from 
the plate using scalpel and collagen I expression was determined using Real-Time PCR. 
 
Real-Time PCR 
Acquisition was done using Step One Plus Real-Time PCR system (Applied Biosystems, 
CA). Analysis of results was done using Step One Software v. 2.1 (Applied Biosystems, 
CA). All preparation steps as well as analytical procedures were done according the 
manufacture protocol.  
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CHAPTER 4 
ISOLATION OF PLACENTAL MSCs   
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CHAPTER 4 
 
This chapter of the thesis is published as per-reviewed article entitled as “Multipotent 
mesenchymal stem cells from human term placenta: critical parameters for the 
isolation and maintenance of stemness after isolation” (AJOG 2010; 202: 193.e1-13). 
Stem cell isolations were done in cooperation with Dr. Antoine Malek. 
Immunocytochemical analysis was performed by Dr. Sonya Koestenbauer.   
4.1. Potential of mesenchymal stem cells for regenerative medicine 
As was mentioned in the introduction mesenchymal stem cells (MSCs) represent an 
interesting cell type for research and therapy because of their ability to differentiate into 
mesodermal lineage cells, such as osteocytes, chondrocytes, cardiac muscle, or 
endothelial cells [141]. In addition, they secrete large amounts of proangiogenic and 
anti-apoptotic cytokines and possess remarkable immunosuppressive properties [142, 
143]. Mesenchymal stem cells have been derived from many different organs and tissues 
[144]. Evidence has emerged that also different parts of human placenta, umbilical cord, 
and amniotic membrane, as well as umbilical cord blood, harbour MSCs [105, 145-148]. 
These tissues are normally discarded after birth, avoiding ethical concerns [149]. 
Mechanical, as well as enzymatic, methods for MSC isolation from different regions of 
human placenta of different gestational ages were reported [106, 141, 148, 150-163]. 
Knowledge about vitality, karyotype, phenotype, and expandability of such placenta-
derived MSC isolates is a prerequisite for therapeutic application; however, systematic 
investigations into reliability of this MSC source and phenotypic stability have not yet 
been attempted. Furthermore, former reports on placenta-derived MSCs often lack 
information about the karyotype of the cell isolates. In this chapter, I described 
enzymatic fractionation of term human placenta that allows recovery of multipotent, 
fibroblast-like cells, which were then used for engineering of stem cell sheets as 
described in the subsequent chapters. I tentatively term these cells as placenta-derived 
mesenchymal stem cells (PD-MSCs) with high fidelity.  
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4.2. Isolation and characterization of MSCs from human term placenta 
The flow chart of the enzyme-mediated fractionation of human term placenta for 
derivation of fibroblast-like cells, which I tentatively term placenta-derived multipotent 
mesenchymal stem cells (PD-MSCs), is depicted in [Figure 24]. Selection for MSCs 
rested on the classic adhesion method on tissue culture plastic. The protocol proved 
successful in 14 of 17 test cases. Cell suspensions produced from final collagenase I 
digest of approximately 15 g placental tissue fragments typically produced 300–500 
colonies of variable sizes that contained outgrowing fibroblast-like cells. Typically, 
approximately 4–6 x 104 cells were obtained within 2 weeks after plating. Plating of cell 
suspensions from the first digest with trypsin did not produce any colonies. Outgrowing 
cells when harvested and plated again in high dilution rapidly formed secondary 
colonies from single cells [Figure 25, A]. Cultures of PD-MSCs were expandable up to 
passage 20 (as far as we cultured) without change of fibroblast-like morphology 
[Figure 25, B] or proliferation rate [Figure 25, C].  
 
   A         B       
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Figure 25: Morphology and growth kinetics of PD-MSCs. (A) Secondary colony formation 
from single cells. Cell shape and organization were analysed by fluorescence microscopy to 
visualize phalloidin stained F-actin cytoskeleton (red) and DAPI stained cell nuclei (blue). 
Phase microscopic images of PD-MSCs at indicated passages (B). Growth kinetics of PD-
MSCs at indicated passages (C). Mortality rates at indicated passages (D) Asterisk indicates 
significant enhancement (P <.05) of cell numbers between time points. 
 
Chromosomal analysis of cell isolates from 6 different placental cases (3 of female and 3 
of male deliveries) did not show any chromosomal abnormalities [Figure 26]. 
C
e
ll 
am
o
u
n
t 
C
e
ll 
am
o
u
n
t 
80 
   
Karyotypes were normal 46, XX in all test samples, including the 3 PD-MSC isolates 
obtained from male deliveries [Table 2]. 
 
 
Figure 26: Representative example of chromosome analysis of PD-MSC cultures at passage 
3 (n=6) 
 
DONOR FOETUS NORMALITY KARYOTYPE
2
4
7
9
11
13
Female
Female
Female
Female
Female
Female
Normal
Normal
Normal
Normal
Normal
Normal
46 XX
46 XX
46 XX
46 XX
46 XX
46 XX
 
 
Table 2: Cytogenic analysis of PD-MSCs. Data represent karyotyping of passage 3 cell 
isolates obtained from three female and three male deliveries.    
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FISH analysis for the SRY gene confirmed the absence of male cells in our PD-MSC 
isolates. Thus, our procedure isolated only PD-MSCs of maternal origin, which was 
unexpected. The phenotype of the cell isolates, passage 1, was examined by flow 
cytometry for 5 subjects [Figure 27] and further examined by immunocytochemistry 
with a panel of antibodies against 30 antigens for a single subject [Figure 28]. 
 
A 
 
Expression in % 
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Figure 27: PD-MSC phenotype at passages 1 and 20 as determined by flow cytometry. 
Screen of PD-MSC isolates at passage 1 (n = 5) shown in blue colour, and passage 20 (n = 5) 
shown in red colour (A). Representative example of PD-MSC isolates at passage 1 (B). 
Green lines denote unstained control cells.  
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Flow cytometry revealed very little scatter in the phenotypic marker profile of placenta-
derived isolates between cases. The expression profile conformed to the criteria recently 
defined for multipotent mesenchymal stem cells [Figures 27 A,B] [164].  Cell isolates 
were uniformly positive for mesenchymal stem cell markers CD44, CD73, CD90, CD105, 
and CD166. Hematopoietic markers CD34 and CD45, as well as CD11b, CD14, CD19, and 
CD79-alpha, were not expressed. Cells stained also negative for macrophage-restricted 
antigen CD163, which marks Hofbauer cells, the cytotrophoblast-specific marker 
Cytokeratin and syncytiotrophoblast-specific marker placental alkaline phosphatase 
[147, 165, 166]. Curiously, the entire cell population was positive for 2 markers of end-
differentiated cells, such as the endothelial protein vWF, and the smooth-muscle cell 
protein-SMA. Isolates of PD-MSCs were negative for kinase insert domain-containing 
receptor, Cytokeratin 18, CD117, and CD271. We found high levels of human leukocyte 
antigen (HLA)-ABC (MHC class I cell surface receptor) but no HLA-DR (MHC class II 
cell surface receptor). Both flow cytometry and immunocytochemistry revealed that part 
of the passage 1 cells expressed the antigen CD133, which is considered as a marker of 
non-committed early progenitors of blood cells, endothelial cells, and other stem cell 
types [167, 168]. Immunocytochemistry did not detect expression of human stem cell 
markers of pluripotency, such as the transcription-binding domains Oct3/4, Stro-1, Tra-
1-60, or Tra-1-81. Flow cytometry and immunocytochemistry revealed that PD-MSCs 
were positive for stage-specific embryonic antigen SSeA-3 but negative for SSeA-4 
[Table 3 and Figures 28].  
Specific induction of differentiation was investigated with PD-MSCs of passage 6, from 3 
subjects. This confirmed that the mesenchymal stemness profile by PD-MSC 
populations indeed associated with the ability to generate different mesodermal lineage 
cell types on their exposure to soluble factors in vitro [169]. Representative results of 
adipogenic [Figure 29, A and B], chondrogenic [Figure 29, C and D], and 
osteogenic [Figure 29, E and F] differentiation assays, visualizing lipid vacuoles, 
chondrogenic matrix, and calcium deposits, respectively. Moreover, culture in presence 
of the angiogenic growth factor VEGF induced expression of marker CD34, which is a 
marker of hematopoietic, as well as endothelial, precursors [Figure 29, G and H] 
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[170]. The latter finding points to a broader mesodermal differentiation capacity of PD-
MSCs. 
 
A 
 
 
Figure 28: PD-MSC phenotype at passage 6 (n=1) as determined by immunocytochemistry. 
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Figure 28: PD-MSC phenotype at passage 6 (n=1) as determined by immunocytochemistry. 
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Figure 29: A representative differentiation of PD-MSCs, passage 6, is shown. Cells were 
kept in induction medium (differentiation) or maintained without induction in standard 
medium (control). Adipogenic differentiation and control as determined by Oil-Red-O 
staining of lipid droplets (A, B); chondrogenic differentiation as determined by Alcian Blue 
staining of proteoglycans (C, D); osteogenic differentiation, as determined by Alizarin Red 
S staining of calcium deposition (E, F); endothelial differentiation and control, as 
determined by CD34 expression in green (G, H). 
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ANTIGEN FACS IC
CD11b - N.D.
CD14 - N.D.
CD19 - N.D.
CD34 - -
CD44 - +
CD45 - -
CD54 N.D. 20%
CD73 + +
CD79a - N.D
CD90 + +
CD105 + 30%
CD117 - -
CD133/1 + 33%
CD163 - N.D
CD166 + +
CD271 - -
Cytokeratin-7 - N.D
Cytokeratin-18 N.D. 40%
VEGF receptor / KDR - -
Placental Alkaline Phosphatase - -
α-Smooth Muscle Actin + +
Von Willebrandt Factor + +
Hepatocyte Specific Factor N.D. -
HLA-ABC + +
HLA-DR - -
SSeA-3 + +
SSeA-4 - -
Oct-3/4 N.D. -
Vimentin N.D. +
Nestin N.D. 50%
E-Cadherin N.D. 40%
ESCM Tra-1-60 N.D. -
ESCM Tra-1-81 N.D. -
ZO-1 N.D. -
 
Table 3: Phenotypic analysis of PD-MSCs by flow cytometry and immunocytochemistry 
4.3. Long term cultivation and differentiation of placental MSCs 
Sub-confluent culture was found critically important to maintain the stemness 
phenotype of PD-MSCs during expansion. The results of a side-by-side screen for 
marker profiles of PD-MSCs that were grown at confluent versus sub-confluent culture 
88 
   
conditions until passage 10 are depicted on the [Figure 30]. The screen was performed 
with 4 cases of each condition. The phenotypic profile of PD-MSCs when sub-cultured at 
50–70% cell density remained unaffected. In sharp contrast, PD-MSCs grown in 
confluent or near confluent culture lost mesenchymal stem cell markers almost 
completely. Expression of CD133 antigen disappeared during culture in both conditions. 
PD-MSCs passaged in sub-confluent culture maintained their initial marker profile and 
their ability to differentiate as well. A direct comparison of the marker profiles of 
passage 1 PD-MSCs versus passage 20 PD-MSCs is depicted on the [Figure 27]. 
Passage 20 PD-MSCs could be induced toward chondrogenic and osteogenic lineage in 
vitro, as demonstrated by staining of chondrogenic matrix and calcium deposits, 
respectively [Figure 31], whereas adipogenic differentiation failed (data not shown). 
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Figure 30: PD-MSC phenotype in sub-confluent versus confluent subculture. Screen of PD-
MSC isolates, passage 10 (n=5). Sub-confluent (blue) culture was found critically 
important to maintain MSC marker expression (A). Representative example of PD-MSC 
isolate at passage 10. (B) 
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Figure 31: Cells were kept in induction medium (differentiation) or maintained without 
induction in standard medium (control). Chondrogenic differentiation and control, as 
determined by Alcian Blue staining of proteoglycans (A, B); osteogenic differentiation and 
control, as determined by Alizarin Red S staining of calcium deposition (C, D).  
4.4. Placenta-derived mesenchymal stem cells for cell sheet engineering 
In demonstrating that term human placenta, which is a readily available and ethically 
relatively unproblematic tissue, constitutes a robust source of MSCs, we investigated 
several parameters - namely, (I) chromosome number, (II) origin, (III) methods of 
isolation, and (IV) propagation - that are important for their principal utility for cell-
based therapy and could influence their proliferative, as well as differentiation, 
capacities. Chromosome number was found normal in all analysed PD-MSC isolates 
(n=6). Looking at maternal or foetal origin, we found that PD-MSC isolates obtained 
with our isolation procedure were always of maternal origin, which was contrary to our 
expectations. This finding corroborates the very recent observation by Barlow et al. that 
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cells isolated from placentas of male delivered babies were not of foetal origin [163]. In 
contrast, the study by Fukuchi et al., which is the only investigation, reported the 
detection of foetal origin cells isolated from human term placenta [154]. However, 
looking at the image provided in the same study, a fraction of the isolated cells was of 
foetal origin, whereas the remaining cells were of maternal origin.  
The precise placental anatomic origin of the maternal cells obtained with our procedure 
is still unclear. One source could be maternal decidua, despite our careful attempts to 
remove this layer completely before digestion of placenta. Placental septa constitute 
another potential source. One explanation for the obvious difficulty to capture foetal 
mesenchymal stem cells from term human placenta is offered by the fact that most stem 
cells observed in the first trimester of pregnancy are differentiated to cytotrophoblast 
and endothelium cells in terminal and intermediate villi, whereas the few remaining 
stem cells were detectable only around the stem villi [171, 172]. Furthermore, the 
thinning of the stromal layer and decreased cell density toward the end of gestation is 
known as a positive adaptation to ensure the increasing nutritional supply of the 
growing foetus [173]. We think that the most likely origin of the maternal cells obtained 
in our study is decidual tissue that remained on placental septa, which is difficult to 
remove. Our method of cell isolation by way of sequential digestion of the trophoblast 
cell layer with trypsin and following digestion of remaining placental tissue with 
collagenase I proved very effective for obtaining PD-MSCs. Outgrowth of PD-MSCs from 
collagenase digests was successful in 14 of 17 test subjects and resulted in populations 
with remarkably little scatter in their MSC profiles, between subjects. As for 
propagation, we found out that PD-MSCs must be propagated in sub-confluent culture 
to maintain their MSC profile, because confluent culture led to gradual loss of MSC 
identity. With proper sub-confluent passage, PD-MSCs maintained their phenotypic 
MSC profile up to the highest passage number we tested in this study, passage 20, as 
well as their differentiation capacity. As detailed above cultures of PD-MSCs, after 1 
passage, were constituted by a homogenous population of fibroblast-like cells, which 
expressed the typical mesenchymal stem cell markers but showed no contamination 
with macrophages, hematopoietic cells, or trophoblast cells [Figure 27]. We observed 
by flow cytometry and immunocytochemistry that early passage cultures expressed 
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CD133, a protein of unknown functionality that is considered a marker of immature 
cells. CD133 expression has been found restricted to stem cells in normal adult tissue 
and expressed by non-committed early progenitors of blood cells and endothelial cells, 
non-malignant neural progenitors, but also as tumour-initiating stem cells in brain [167, 
174, 175]. Recent studies showed that CD133-positive cell fractions of mononuclear cell 
human peripheral blood and cord blood, which were isolated by magnetic sorting with 
micro-beads coated with anti-CD133 antibody, give rise to MSCs [168]. Magnetic sorting 
of CD133-positive cells from placental extracts, therefore, could provide an alternative to 
MSC selection by adhesion to tissue culture plastic. The growth potential of PD-MSCs, 
as assessed by their growth kinetics at passages 1, 10, and 20, was unaffected by 
subculture. Furthermore, our studies of stemness in functional differentiation assays 
showed that PD-MSCs retain their ability to generate chondrocytes and osteocytes at 
passage 20, although adipogenic potential was obviously lost at late passage. Induction 
with VEGF of endothelial differentiation in early-passage PD-MSCs showed that the 
induced cells expressed CD34, a marker for endothelial precursors. We strongly caution 
about an interpretation that PD-MSCs could differentiate into endothelial cells but 
rather believe that this finding could point to a broader plasticity of PD-MSCs. 
4.5. Achievements of the fourth chapter 
In the first part of my thesis I developed a highly reproducible, straightforward 
methodology that leads to isolation of multipotent mesenchymal stem cells of maternal 
origin from human term placentas. These cells were then used for generation of stem 
cell sheets. Further studies in this direction are indicated to evaluate the properties of 
such maternally derived PD-MSCs regarding their full differentiation capacity in vitro 
and ultimately in vivo. Aside from evaluating their utility for future cell replacement 
therapy and tissue engineering, we seek to resolve whether such PD-MSC isolates could 
become exploited in transplantation medicine for an ability to exert immunosuppressive 
effects and/or to secrete proangiogenic and antiapoptotic cytokines to aid tissue healing 
[142, 176]. 
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CHAPTER 5 
STEM CELL SHEET ENGINEERING ON PEM 
SUBSTATES  
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CHAPTER 5 
 
This chapter of the thesis is published as per-reviewed article entitled as “Engineered 
polyelectrolyte multilayer substrates for adhesion, proliferation, and differentiation of 
human placental mesenchymal stem cells. (TISSUE ENGINEERING Part A Volume 15, 
Number 10, 2009). Confocal microscopic analysis was performed in cooperation with 
Dr. Anne-Greet Bittermann.   
5.1. Polyelectrolyte multilayer (PEM) substrates 
Polyelectrolyte multilayer assemblies (PEM) can be generated from very broad range of 
natural and synthetic materials. Among them are: poly amino acids (poly-L-lysine 
(PLL), poly-L-(glutamic acid)), polysaccharides (hyaluronic acid (HA), dextran sulphate, 
and chitosan), or synthetic polymers (poly (allylamine hydrochloride), poly-methacrylic 
acid, or sulfonated poly-(styrene)) [177]. Adsorbent species, time of adsorption, and 
concentration of adsorbed polyelectrolytes but, importantly, also the conditions under 
which PEMs are built up (pH, rinsing solution, ionic strength, number of layering steps, 
assembly order, chemical cross-linking) dictate the morphology, thickness, and internal 
structure of the coatings, which in turn determine their distinctive bioactivity. Coatings 
assembled from PEM with highly adjustable bioactive properties were demonstrated. 
For example, varying the build-up pH or ionic strength directed single multilayer 
combinations to be adhesive versus resistant surfaces for fibroblasts or to be anti-versus 
pro-coagulate surfaces [177, 178]. Coatings built from PEM can also serve as reservoirs. 
Various compounds such as DNA, RNA, drugs, dyes, inorganic particles, proteins, and 
peptides can be embedded in PEMs or deposited on top of them. For embedded peptide 
hormones or antibodies, the biological activities were found to be retained [139, 179, 
180]. Several studies have recently investigated cell interactions with PEMs. The 
biophysically and biologically best-studied systems are arguably multilayer coatings of 
anionic HA and cationic PLL [132, 181, 182]. Even micrometre-thick films of (PLL/HA)i 
have been achieved, where i is the number of layer pairs [183]. HA is a natural, linear 
polysaccharide with repeating disaccharide units of D-glucuronic acid and N-acetyl-D-
glucosamine with b (1P4) interglycosidic linkage and is found in the extracellular matrix 
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of connective tissue, where it is present as a hydrated network with collagen fibres. Its 
average molar mass ranges from approximately 105 to 107 Da. HA provides excellent 
biocompatibility, and native and modified HA have been used for ophthalmic surgery, 
arthritis treatment, drug delivery, and tissue engineering [184]. The counter polycation 
PLL is widely used in cell culture to promote cell adhesion to solid substrates and can be 
easily conjugated with bioactive molecules. Mechanistic studies indicated that 
(PLL/HA) multilayer build-up begins with isolated islands that grow by addition of new 
polyelectrolytes on their top and by mutual coalescence and that continuous films are 
obtained after the eighth layer pair deposition [132]. Native, as-built PEM coatings are 
soft, elastic substrates that did not support cell adhesion well. Increasing stiffness of 
(PLL/HA) multilayers was most influential for cell adhesion [139]. Using chemical 
cross-linking of (PLL/HA) multilayers by water-soluble carbodiimide in combination 
with N-hydroxysulfosuccinimide coatings were obtained with an effective Young‟s 
modulus that was more than 10 times as large as in a native, non-cross-linked multilayer 
substrate [182]. Tests of cross-linked (PLL/HA) multilayer substrates with primary 
chondrocytes and smooth muscle cells showed greater cell anchoring and spread on the 
cross-linked layers [139, 185]. 
As was mentioned in the first part of the thesis, mesenchymal stromal cells (MSCs) 
represent a particularly interesting cell type for research and therapy because of their 
ability to differentiate into mesodermal lineage cells such as osteocytes, chondrocytes, 
cardiac muscle, and endothelial cells [154].  In addition, they secrete large amounts of 
pro-angiogenic and anti-apoptotic cytokines, and possess remarkable 
immunosuppressive properties [155, 156, 186]. Nowadays, MSCs have been derived 
from many different organs and tissues, but much of the literature is on MSCs from 
bone marrow or adipose tissue [187]. Recently developed a general, minimal working 
definition of MSC isolates that rests on three criteria: plastic adherence at in vitro 
culture; molecular surface profile (expression of CD105, CD73, and CD90 but lack of 
CD45, CD34, CD14 or CD11b, CD79alpha or CD19, and human leukocyte antigen DR); 
and in vitro differentiation into osteoblasts, chondrocytes, and adipocytes. These 
criteria apply to the human placenta-derived MSCs and human adipose tissue-derived 
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MSCs, which were used in the present study [188]. Interactions between MSCs and PEM 
substrates have not been studied before.  
5.2. Interactions between MSCs and native (PLL/HA) substrates 
To promote interactions with MSCs, the following parameters of PLL/HA multilayer 
build-up were controlled. (I) Thickness was varied according to the number of PLL/HA 
layer pairs. (II) Cell adhesiveness was approached through deposition of cell adhesion 
glycoprotein FN as the outermost layer. (III) Stiffness of the multilayer was increased by 
introducing covalent cross-links and amide bonds between HA and PLL. (IV) FN was 
covalently affixed or physically adsorbed onto multilayer. Coatings were prepared with 
three-, six-, or nine-layer pairs of (PLL/HA), followed by an end layer of positively 
charged PLL and the final (optional) adsorption of FN. The resulting constructs were 
designated (PLL/HA)i- PLL-FN, where i is the number of layer pairs. The stepwise 
adsorption of PLL, HA, and FN as monitored in situ by OWLS as the example of a 
(PLL/HA)9 coating is depicted on the [Figure 32A]. OWLS showed successful 
adsorption of FN, which assumed surface densities between 350 and 700 ng/cm2 on 
three-, six, or nine-layer-pair constructs [Table 4]. These adsorbed FN surface 
densities are biologically significant. Saturation levels from 350 to 400 ng/cm2 were 
previously reported to represent approximately the amount of FN necessary to produce 
a monolayer coating based on the dimensions of the molecule [189, 190]. Such densities 
are known to support strong cell adhesion on solid synthetic surfaces as well as on thin 
multilayer films [191]. None of the FN-terminated (PLL/HA) multilayer substrates, 
when used as built, functioned as adhesive substrate for PD-MSCs or AT-MSCs [Figure 
32 B]. Both types of MSCs seeded at density 3.5 x 104 cells/cm2 attached poorly. This 
was not from the toxicity of the PEM compounds, because cells could adhere and spread 
at the bottom of the same well on the tissue culture plastic near the coated glass slide 
(not shown). It was also not from loss of function of FN from its adsorption to PEM 
substrate. We tested the mouse myoblast cell line C2C12, which was previously used to 
examine effects of substrate-dependent changes in FN conformation for integrin ligation 
and cell adhesion on synthetic surfaces [189]. All native (PLL/HA)3,6,9-PLL-FN 
multilayers were adhesive for C2C12 cells, and under the high seeding density 
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conditions of this experiment, complete cell monolayers formed within 24 h [Figure 
32B]. We concluded that native, as-built (PLL/HA)i-PLL-FN layers were inadequate 
surfaces for MSC adhesion. 
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Figure 32: MSCs do not adhere to native cationic poly-L-lysine and anionic hyaluronic acid 
(PLL/HA) multilayer coatings. (A) Representative optical waveguide light mode 
spectroscopy (OWLS) measurement of PLL/HA multilayer build-up using the example of a 
nine-layer pair coating. Coatings were prepared with a PLL end layer and terminated with 
adsorbed fibronectin (FN). Subsequent cross-linking was also followed in situ using 
OWLS. (B) Phase micrographs of MSC cultures on (PLL/HA)i-PLL-FN multilayer coatings 
48 h after seeding, where i denotes the number of PLL/HA layer pairs. Bar size: 100 m 
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5.3. Interactions between MSCs and cross-linked (PLL/HA) substrates 
Recent studies of (PLL/HA) multilayer surfaces have revealed that stiffening of bulk 
multilayers enhanced adhesion of smooth muscle cells, chondrosarcomic cells, or 
osteoblasts [139, 181, 192]. Protocols have been described for controlled stiffening of 
(PLL/HA) bulk multilayers by converting the purely electrostatic cross-linking of the 
native multilayers (ionic interactions) to covalent cross-linking between ammonium 
groups of PLL with carboxylate groups of HA (amide bonds) using EDC in combination 
with sulfo-NHS [182, 193]. We tested (PLL/HA)9-PLL-FN multilayers cross-linked to 
different degrees by varying concentration of EDC from 0 to 800 mM in the EDC/NHS 
cross-linking mix for their ability to mediate PD-MSC adhesion [Figure 33]. Phase 
microscopy 72 h after cell seeding showed that a gradual increase of multilayer stiffness 
correlated with a gradual increase of well-spread, elongated PD-MSCs with well-
organized actin fibres. MSCs on native (EDC 0) or low-cross-linked (PLL/HA) 
multilayers (EDC 8) remained roundish and loosely attached to the multilayers; they 
lacked actin fibres or displayed cortical actin organization. Visual inspection indicated 
that multilayer coatings formed under the highest cross-linking regime, EDC 800, were 
optimal for MSC adhesion.  
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Figure 33: Stratification of stiffened multilayers for promotion of MSC adhesion. (A) 
Determination of cell densities on native multilayers or multilayers cross-linked with EDC. 
(B) Images show PD-MSCs on PLL/HA multilayers that were stiffened to various degrees 
by crosslinking with increasing concentrations of N-(3 dimethylaminopropyl-N)-
ethylcarbodiimide hydrochloride (EDC) in combination with a fixed concentration of 
100mM N-hydroxysulfosuccinimide sodium salt. The EDC numbers indicate the milli-
molar concentrations of EDC in the cross-linking mix. Images were taken 72 h after cell 
seeding. Phase contrast microscopy of cell morphology and fluorescence microscopy of 
actin cytoskeleton (red colour) show that stiffer coating correlated with greater cell 
anchoring and spreading. Cell nuclei were stained with 4,6-diamidino-2-phenylindole 
dihydrochloride (DAPI; blue colour). Bar size: 50 µm.  
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Phase microscopic follow-up of low-density MSC cultures on cross-linked multilayers 
showed that MSCs maintained their ability to proliferate [Figure 34 A]. Cell counts 
obtained from DAPI-stained cultures revealed that PD-MSCs and AT-MSCs exhibited 
similar proliferation rates [Figure 34 B]. 
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Figure 34: Proliferation of MSCs on cross-linked multilayers. (A) Phase microscopic 
monitoring of MSC cultures on (PLL/HA)9-PLL-FN multilayers cross-linked with the EDC 
800 regimen. Bar size: 100 mm. (B) Proliferation rates of PD-MSCs (blue) and human 
adipose tissue–derived MSCs (AT-MSCs) (red) on multilayers. Cell counts were 
determined from fluorescence micrographs of DAPI-stained cultures with image analysis 
software.  
 
The stiffening of the bulk layer produced a strong positive effect for cell adhesion and 
outgrowth for multilayers of all thickness (i.e. (PLL/HA)-PLL-FN constructs with three-, 
six-, and nine-layer pairs) [Figure 35]. According to gross visual analysis, the positive 
effect of crosslinking for MSC adhesion appeared comparable between multilayers of 
different thicknesses. Cultures of MSCs seeded at density 3.5 x104 cells/cm2, formed 
dense PD-MSC and AT-MSC layers 48 h after seeding [Figure 35 A]. Quantitative 
analysis revealed that PD-MSC densities on multilayers from six and nine PLL/HA pairs 
were significantly higher (p<0.05) than those on three PLL/HA pairs [Figure 35 B]. 
Multilayer thicknesses did not affect AT-MSC densities. Without cross-linking, cell 
densities were low [Figure 35 B]. Summary of the results is shown in [Table 4]. 
As next, I investigated the effect of cross-linking for the FN outer layer. For that, we 
compared the distribution of FN on cross-linked and native (PLL/HA)9 layers, using 
fluorescently labelled FN, confocal microscopy, and data processing with Imaris imaging 
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software. Three layer preparations with FN were compared: native bulk layer with 
physically pre-adsorbed FN, cross-linked bulk layer followed by physically pre-adsorbed 
FN, and cross-linked bulk layer with cross-linked FN [Figure 36].  
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Figure 35: Stratification of multilayer thickness for MSC adhesion. (A) Phase micrographs 
of MSC cultures. i denotes the number of PLL/HA layer pairs. According to gross visual 
examination with phase microscopy, there was no difference between cell densities on 
multilayers of different thickness. Bar size: 100 µm. (B) Quantitative comparative analysis 
of cell densities on cross-linked and native PLL/HA multilayers, was performed using 
crystal violet staining and colorimetric analysis. In case of PD-MSCs, cell densities on 
cross-linked six- or nine-layered PLL/HA constructs were significantly greater than those 
on PLL/HA constructs with three layer pairs. In all constructs, the effect of cross-linking 
for greater cell density was highly significant compared with native ones. *denotes p<0.05 
versus native constructs; #denotes p<0.05 versus PD-MSCs on coatings with three layer 
pairs. 
THICKNESS NATIVE PEM CROSS-LINKED PEM
(PLL/HA)i-PLL FN (ng/cm)2 PD-MSC AT-MSC C2C12 PD-MSC AT-MSC
i=3
i=6
i=9
350
550
750
poor
poor
poor
poor
poor
poor
complete
complete
complete
complete
complete
complete
complete
complete
complete
 
 
Table 4: Adhesion of different cell types on (PLL/HA) coatings depending on the thickness 
of the coating. AT-MSCs – adipose tissue derived mesenchymal stem cells, PD-MSCs – 
placenta-derived mesenchymal stem cells, C2C12 – mouse myoblasts.  
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Figure 36: Cross-linking of PLL/HA layers affects FN surface distribution. Confocal 
microscopy of native or cross-linked (PLL/HA)9 multilayers formed with a physically 
adsorbed or chemically coupled FN outer layer. The green colour represents the 
fluorescently labelled FN. (A) Native PLL/HA multilayer with adsorbed FN. (B) Cross-
linked PLL/HA multilayer with adsorbed FN. (C) Cross-linked PLL/HA with cross-linked 
FN. Top row, three-dimensional reconstitutions of FN top layers with Imaris software. Bar 
size: 30 mm. Middle row, side views of the FN interfaces. Bottom row, top views of the FN 
interfaces; the high magnification images were produced using a 7 x electronic zoom. Bar 
size: 4.3 µm. 
 
This analysis revealed different FN surface patterns. Top- and side-view images of 
illustrate the different FN interfaces [Figure 36]. Native and cross-linked PEM layers 
with physically adsorbed exhibited a diffuse, spotty, and spiky surface distribution of FN 
[Figure 36 A and B]; by contrast, chemically coupled FN appeared condensed in a 
narrow zone [Figure 36 C]. At the resolution of our confocal microscope, the 
chemically coupled FN appeared as fine regular mesh forming from coalescing droplets. 
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The condensed distribution of chemically coupled FN suggests greater FN surface 
density at the interface with cells. The stiffening of PEM layers by cross-linking along 
with concomitantly greater FN ligand density at the cell – (PLL/HA) coating interface 
had a profound effect on focal adhesion formation of MSCs, as demonstrated by 
immunofluorescence staining for vinculin, a component in the focal adhesion protein 
complex [Figure 37].  
 
 
 
Figure 37: Immunofluorescent staining for focal adhesion formation on native and cross-
linked FN-terminated (PLL/HA)9 layers. Cells were stained for focal adhesion protein 
vinculin (green) and cell nuclei counterstained with DAPI (blue). Confocal images of PD-
MSCs on (A) native and (B) cross-linked PLL-HA layers. (C) C2C12 mouse myoblasts on 
native and (D) cross-linked PLL/HA layers. Bar size: 30 µm.  
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MSCs grown on cross-linked PEM layers, but not those on native PEM layers, showed 
punctuate expression of vinculin at the tips of elongated cell structures [Figure 37 A, 
B].  
These results indicate that the functionality of FN for binding to the FN adhesion 
receptor, integrin α5β1, on cells was not affected. MSCs did not attach and spread well 
on cross-linked (PLL/HA) layers with physically adsorbed FN (data not shown). Parallel 
vinculin staining of the murine C2C12 myoblasts also showed focal adhesions on native 
layers and little effect of cross-linking the bulk layer and FN [Figure 37 C, D]. 
However, we noted that cell areas of C2C12 cells on native layers often appeared larger 
than on cross-linked layers, and cells exhibited many filopodia. In conclusion, cross-
linked PLL/HA multilayer substrates formed with cross-linked FN possess better 
adhesion properties for MSCs.  
Our next steps of investigation concerned long-term stability of densely grown MSC 
cultures and their differentiability on (PLL/HA) multilayers. We examined the role of 
the outer layer of FN for stability of dense MSC cultures, comparing side-by-side 
physically adsorbed FN with covalently affixed FN [Figure 38].  
Covalent binding of FN to multilayers was critical for maintenance of dense MSC 
cultures, whereas purely physical FN adsorption performed insufficiently [Figure 38 
A]. Only MSC cultures on covalently cross-linked FN were complete after 1 week 
[Figure 38 B]. Beyond this period, the cultures gradually began to detach focally 
(holes in the cell layer), especially under the conditions of differentiation culture in 
osteogenic or chondrogenic medium; spontaneous lift of MSC layer as sheets rolling up 
from the edges was occasionally observed [Figure 38 C].  
Cultures of PD-MSC and AT-MSC (data not shown) on cross-linked (PLL/HA)9-PLL-FN 
remained capable of differentiating into mesodermal lineages, as demonstrated by 
biochemical stainings for chondrogenic and osteogenic differentiation markers, 
respectively [Figure 39].  
Differentiation of PD-MSCs and AT-MSCs towards adipogenic lineage on cross-linked 
(PLL/HA)9-PLL-FN substrates was not successful. 
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Figure 38: The role of terminal multilayer-bound FN for initial MSC monolayer formation. 
(A) Native and cross-linked (PLL/HA)9-PLL multilayer constructs were prepared with or 
without FN and seeded with PD-MSCs and AT-MSCs. Phase micrographs of MSC cultures 
on multilayer 48 h after seeding. Stiffness, as accomplished using EDC=NHS crosslinking 
of multilayers, was critical. Pre-adsorption of FN showed unnecessary for initial adhesion 
and outgrowth of MSCs. (B, C) Effect of physical FN adsorption (B) versus chemical cross-
linking of FN (C) to PLL/HA multilayers for maintenance of MSC layers. Images show 
crystal violet stained PD-MSCs monolayers after 1 week in culture. Covalent affixation of 
multilayer-bound FN proved important for preventing partial detachment.  
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Figure 39: Multilayer-bound MSCs remain capable of mesodermal lineage differentiation 
upon culture with soluble induction factors. Images show PD-MSC cultures on (PLL/HA)9-
PLL multilayers with covalently affixed FN. (A) Induced osteogenic differentiation of PD-
MSCs. The differentiated PD-MSCs were stained for ALP activity. (B) Control culture in 
standard medium showed no differentiation. (C) Induced chondrogenic differentiation 
was demonstrated by immunofluorescent staining with antibodies for collagen II (green). 
Cell nuclei were counterstained with DAPI (blue). (D) Control culture in standard medium 
showed no differentiation. Blue, DAPI stained nuclei. Bar size: 50 µm. 
5.4. Relevance of (PLL/HA) substrates for stem cell sheet engineering 
For full PEM-driven control of cellular response, continuous PEM coating was sought to 
minimize influences from the underlying glass substrate on which the PEM coatings 
were built up. Deposition of eight-layer pairs of (PLL/HA) was previously found to be 
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sufficient to produce continuous PEM coating with a smooth surface, which was 
confirmed under our deposition conditions [132]. This can be readily appreciated from 
the image given showing a (PLL/HA)9 coating with an experimental scratch to prove the 
coating [Figure 40].  
 
 
Figure 40: Deposition of nine PLL/HA layer pairs produced continuous films. The coating 
was prepared on glass coverslips as described in the Methods section. An experimental 
scratch was created to demonstrate the continuous coating. The phase micrograph image 
was taken with a Leica DMIL fluorescence microscope equipped with a DML digital camera 
(Leica) at the 40x magnification. 
 
Numbers (PLL/HA) layer pair did not influence MSC adhesion in the native or cross-
linked condition, which suggests that the influence of the glass substrate on MSC 
adhesion response was minimal [Figure 33]. The mechanical properties, not the 
thickness, of (PLL/HA) multilayers were critical for MSC adhesion. As shown in earlier 
studies, post-formation chemical cross-linking of PEM layers with EDC/NHS limits 
polyelectrolyte diffusion inside the bulk PEM structure and increases its stiffness 
without significant change of PEM thickness [139]. Fibronectin-terminated (PLL/HA) 
multilayers processed with a high cross-linking regime promoted PD-MSC and AT-MSC 
adhesion instantly and efficiently, whereas native multilayers, which are soft, were 
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almost adhesion-resistant to MSCs [193]. Our findings add to the broad notion that 
adhesive spreading of cells correlate with the effective stiffness of (PLL/HA), as well as 
other PEM coatings, and more generally with the stiffness of synthetic material 
substrates. How MSCs probe and adapt to the stiffer PLL/HA substrate is beginning to 
be understood. Focal adhesions provide MSCs with the necessary force transmission 
pathways to „„feel‟‟ their gel matrix microenvironment through actin-myosin 
contractions [194]. Stiffer substrates produce stiffer and increasingly tense cells [194]. 
Studies with murine NIH3T3 fibroblasts plated on FN-coated polyacrylamide gels 
showed that cells change their internal stiffness, governed by cytoskeletal assembly and 
production of internal stresses, to roughly match the stiffness of the substrate [195]. 
Some cell types seem capable of anchoring even to soft multilayer substrates. We found 
that mouse C2C12 myoblasts, unlike the MSCs, adhered and spread on soft, native 
(PLL/HA) multilayers [Figure 32 B] and formed vinculin-positive focal adhesions 
[Figure 32 C, D]. Reasons for different adhesion responses of MSCs and C2C12 cells 
on native multilayers with surface-adsorbed FN remain speculative. It may be the result 
of different „„inside out‟‟ signalling pathways in C2C12 cells and MSCs that lead to 
different activation stages of the responsible FN adhesion receptor, α5β1. A two-stage 
activation mechanism for α5β1 binding to surface adsorbed FN was described [196]. 
Another possibility is that adsorption of FN to a (PLL/HA) multilayer substrate 
produces a conformational change in FN and that this altered FN is bound by α5β1 on 
C2C12 cells and MSCs at different levels. It has been shown that adsorption of FN to 
substrates changes FN conformation and subsequently alters its binding to the integrin 
α5β1 [189]. Finally, C2C12 myoblasts may possess an inherent natural capacity to 
comply with soft substrate environments. In support of the latter, emerging knowledge 
suggests that cellular responses to substrate stiffness (e.g., for maximal spreading or 
differentiation) are cell-type dependent in that the effective range of substrate stiffness 
depends on the tissue type from which the cells were derived [197]. The reported value 
for elasticity of striated muscle tissue is approximately 8 to 17 kPa, 30 which is within 
the range of elasticity reported for native PLL/HA coatings [193, 198]. Hence, it is 
conceivable that C2C12 myoblasts by nature are better prepared to attach and spread on 
soft PEM substrates. Recent studies have shown that tissue-level matching substrate 
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stiffness strongly affects lineage specification and morphology of human MSCs [194]. A 
simple alteration of substrate compliance evoked specific MSC differentiation (e.g., soft 
polyacrylamide gel substrates that mimic brain were neurogenic, whereas stiff 
substrates that mimic collagenous bone were osteogenic) [198]. In light of this emerging 
knowledge, PLL/HA multilayer substrates may offer great opportunities for compliance-
specific differentiation assays of MSCs, because the Young‟s modulus of PLL/HA 
multilayer coatings can be readily modulated over a range from 0 to 400 kPa, depending 
on their cross-linking degree [193]. Along these lines, it has been reported that 
modulation of stiffness of PLL/HA multilayer substrates in turn modulated C2C12 
myoblast cell differentiation and their organization into myotubes [199]. I investigated 
the role of FN outer layers for MSC culture initiation, focal adhesion formation, and 
maintenance of densely grown MSC cultures. PLL-terminated multilayers were chosen 
for study, because other studies suggested that positive-terminal PEM layers favourably 
influence the distribution of FN molecules by inhibiting their aggregation in the 
adsorption layer, unlike negative-terminal layers [200]. With regard to adsorbed FN 
mass, our OWLS measurements revealed that the negatively charged FN adsorbed to 
terminal layers of HA at a similar level, despite the negative charge and hydrated nature 
of the latter (data not shown). Confocal microscopic analysis of the FN interface 
revealed that crosslinking of FN-terminated (PLL/HA) layers changed the FN 
distribution from diffuse to condensed, resulting in greater presentation of FN adhesion 
sites to cells. Our results showed that the details for preparation of the FN interface on 
(PLL/HA) coatings matter greatly, at least for MSC culture. Only bulk layers with cross-
linked FN were effective substrates for MSCs, which indicates that cross-linking does 
not affect the function of FN. It is likely that the stiffening by cross-linking plus the 
greater FN ligand density at the cell – PEM layer interface resulting from cross-linking 
synergistically accounts for the enhanced MSC spreading and focal adhesion formation 
[Figures 36 and 37]. Physically adsorbed and chemically coupled FN was found 
distributed only at the top of the (PLL/HA) coating. This confirms other studies of FN 
adsorption that have indicated that FN rapidly complexes with PLL with little or no FN 
penetration into the PEM bulk [191]. Covalent fixation of FN to (PLL/HA) coatings 
proved necessary to maintain densely grown MSC cultures during differentiation culture 
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over weeks [Figure 38 B]. The amounts of FN adsorbed to (PLL/HA) multilayers, as 
determined according to OWLS, were 350 to 700 ng/cm2 [Table 4]. These amounts 
favourably compared the (high) plateau densities of adsorbed FN measured on bacterial 
or tissue culture polystyrene [189]. FN is known as flexible glycoprotein with substrate-
sensitive conformations, which in turn can modulate cell proliferation and 
differentiation [189]. Our data indicate that EDC/NHS-mediated cross-linking of 
multilayer-bound FN does not impair its functionality. Similar observations were made 
for collagen coatings cross-linked with EDC/NHS, which led to greater endothelial cell 
adhesion and proliferation on vascular grafts than with physically adsorbed collagen 
[201]. Innovative use of charge-responsive polyelectrolyte coatings could provide a new 
means for non-enzymatic harvest of MSCs and their transplantation as intact, cohesive 
cell sheets into diseased tissues, a concept known as cell sheet engineering [126]. It has 
been already demonstrated that monolayered polycationic copolymer poly(l-lysine)-
grafted-poly(ethylene glycol) that were formed on conducting metal oxide substrate 
desorbed from their metal oxide substrate after the application of a positive potential, 
lifting complete sheets of osteoblasts cultured on the polyelectrolyte monolayer [138]. 
Based on these results I proposed to use (PLL/HA) platform as Innovative charge-
responsive polyelectrolyte coating for non-enzymatic charge-mediated harvest of PD-
MSCs sheets. Surprisingly, my results show that native as-built (PLL/HA) coatings are 
very poor adhesive for PD-MSCs and only the cross-linked, FN-terminated (PLL/HA) 
coatings under present study permitted formation of complete MSC layers [188]. 
Unfortunately, my following experiments have shown that such coatings do not dissolve 
upon electrochemical polarization (unpublished observations). Thus, establishment of 
new alternative multilayer system that might be sufficient for formation and 
electrochemically controlled lift of MSC sheets was needed. 
5.5. Achievements of the fifth chapter 
In the second part of my thesis I established tuneable, polyelectrolyte multilayer 
substrates with biological features and physico-chemical properties that permit 
adhesion, proliferation, and differentiation of human MSCs. I was aiming to evaluate 
usability and functional potential of such type of substrates as a “smart” responsive, 
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biomimetic platform for engineering, characterization, and following non-invasive 
detachment of PD-MSC sheets, by application of electrochemical means [138]. Although 
the developed platform was shown to be not suitable for electrochemical harvesting of 
PD-MSCs this development was still essential to realize that the mechanical properties 
of the polymer substrate affect the cell-surface interactions and cell viability. The results 
of the next chapter therefore are a direct consequence of the findings here. In addition, 
it is quite likely that the cross-linked multilayers of this chapter could also be used for 
the electrochemically induced pH change based harvesting of cell sheets.  
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RECOVERY OF PLACENTAL STEM CELL 
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CHAPTER 6 
 
This chapter of the thesis is published as per-reviewed article entitled as “pH-
controlled recovery of placental mesenchymal stem cell sheets” (BIOMATERIALS 2011, 
32, 4376-4384). Atomic force microscopy analysis, as well as procedure of 
electrochemical peeling was performed by Dr. Orane Guillaume – Gentil. The process 
of stem cell sheet recovery has been microscopically acquired with assistance of Dr. 
Sara Andrea Schaufelberger and Philipp Lieneman.    
6.1. Biomedical applications of stiff (PAH/PSS) multilayer substrates  
Cell sheet engineering has been originally developed using cell culture dishes grafted 
with temperature responsive polymers, showing cell adhesive properties at 37°C, while 
switching to non-fouling properties below 32°C [202]. Later, alternative approaches for 
the release of cell sheets have been proposed, based on enzymatic, electrochemical or 
magnetic triggers [80, 203]. Among those, the electrochemical stimuli are particularly 
attractive due to their spatial and temporal precision, rapidity and reversibility, and the 
possibilities for automation and remote control [Figure 41].  
 
 
 
Figure 41: Cell sheet detachment using electrochemical stimuli. 
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Previous platforms designed for cell sheet release under electrochemical control are 
based on the controlled dissolution of sacrificial substrates made of self-assembled 
monolayers (SAMs) or polyelectrolyte multilayers (PEMs) [138, 204, 205].  
These platforms offer versatile, biocompatible substrates, simple and inexpensive 
processing, precise control, and are applicable to any surface geometries. PEMs in 
particular represent highly promising material for the bio-interface, providing a precise 
control over their chemical, physical, and mechanical properties, and the possibility to 
incorporate bioactive moieties such as drugs, nucleic acids, peptides, proteins or growth 
factors [206].  
PEM coatings composed of poly-(allylamine hydrochloride) (PAH) and poly-(4-styrene 
sulfonate) (PSS), two synthetic polyelectrolytes, recently emerged as excellent cell 
substrates. In vitro, (PAH/PSS) substrates  showed good cell adhesive properties and 
improved cell proliferation for a variety of cell types including endothelial cells [207, 
208], fibroblasts [209, 210], osteoblastic cells [211], and hepatocytes [212], promoted 
adhesion and differentiation of endothelial progenitor cells derived from rabbit 
peripheral blood [213] or human umbilical cord-blood [214], and improved cell growth 
and cell viability of bone marrow-derived human mesenchymal stem cells compared to 
fibronectin-modified surfaces [215].  
The incorporation  of a growth factor or a chemo-repulsive protein into PSS-ending 
multilayers further allowed for the modulation of the growth and survival of neurons 
[216], whereas VEGF embedded in PAH/PSS assemblies enabled the stimulation 
endothelial cells proliferation [217]. While all these studies revealed their promising 
properties in cell studies, (PAH/PSS) coatings were recently evaluated in vivo. In a 
rabbit model, human umbilical arteries treated with (PAH/PSS) multilayers showed 
high graft potency and no inflammation 3 months after implantation, holding great 
promises for small vessel replacement [140].  
When subjected to an electrochemical trigger, (PAH/PSS) were shown to be relatively 
stable, with thin films dissolving only slowly after a prolonged electrochemical 
stimulation. On the other hand the pH lowering, which results from electrochemically-
induced water electrolysis at the electrode surface, was shown to extend a few hundreds 
of nanometre above the thin (PAH/PSS) films [218].  
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The cells cultured on a (PAH/PSS) substrates most probably interact with a layer of 
proteins adsorbed on the polyelectrolyte films from the growth medium or produced by 
the cells. The protein-substrate, protein-protein, and individual protein intra-molecular 
interactions result from the sum of multiple interactions of different nature (ionic, 
hydrophobic, hydrogen bonding, van der Waals, etc.), and subtle changes in the proteins 
microenvironment, such as a decrease in pH, are expected to induce significant changes 
in the adsorbed protein layer [219].  
We therefore speculated that a local, electrochemically-induced pH lowering at the bio-
interface could instigate cell sheet detachment, through perturbation of the protein layer 
on which cells adhere. In third part of my thesis a novel (PAH/PSS) based platform for 
cell sheet engineering is demonstrated, where a local or global pH lowering allowed for 
controlled detachment of PD-MSC sheets. The stability of (PAH/PSS) substrates against 
pH lowering, and their suitability for the culture of PD-MSCs were examined in vitro. 
The compatibility of the harvesting process with regard to the preservation of stem cell 
viability, phenotype and differentiation potential was evaluated.  
6.2. Characterization of (PAH/PSS) substrates 
Poly(allylamine hydrochloride) and poly(styrene sulfonate) (PAH/PSS) multilayered 
thin films were assembled layer-by-layer on indium tin oxide (ITO) electrodes to 
generate substrates for the growth and subsequent harvesting of placenta-derived 
mesenchymal stem cell (PD-MSC) sheets. The deposition of nine bilayers of (PAH/PSS) 
on the electrodes is yielded continuous thin films with a thickness of about 20 nm 
[Figure 42 A and F].  
The stability of the (PAH/PSS)9 substrates in respect to an external electrochemical 
trigger was monitored by EcAFM. Under an applied current density of 30 µA/cm², the 
(PAH/PSS)9 films remained stable for at least 30 minutes, without any changes in the 
thickness or surface roughness (Data not shown). Applying a higher current density 
(100 µA/cm²), no changes in thickness or surface roughness were detected by EcAFM 
measurements within 30 minutes, while a small decrease in thickness indicating the 
dissolution of the coating was detected after 60 minutes [Figure 42 A-E].  
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The stability of (PAH/PSS)9 films was further assessed towards lowering of the bulk pH. 
The coating, prepared under physiological conditions at pH 7.4, was immersed in a 
buffer at pH 4.0 for 2 hours. AFM images showed no changes in the coating thickness 
and surface roughness [Figure 42 F-H]. 
 
 
 
Figure 42: Effect of electrochemical stimuli and bulk pH decrease on (PAH/PSS)9 thin films 
as followed by ecAFM. AFM Height mode images of a (PAH/PSS)9 film deposited on an ITO 
electrode (A), and subsequently subjected to 100 µA/cm² for 15 (B), 30 (C) and 60 (D) 
minutes. The profiles (E), corresponding to the white dashed line in each AFM images, 
showed no significant changes at 15 and 30 minutes, while a slight decrease in thickness 
was observed after 60 minutes. (F) AFM height mode images of a (PAH/PSS)9 film 
deposited on an ITO electrode in HEPES-2 buffer (pH 7.4) and (G) after 2 hours in a buffer 
at pH 4.0. The profiles corresponding to the white dashed lines on AFM images (H) showed 
no changes under the change of bulk pH. The black areas on each image correspond to 
scratches allowing for thickness determination.  
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6.3. Assembling of PD-MSCs sheets on (PAH/PSS)9 substrates 
Placental MSCs (PD-MSCs) were cultured on the (PAH/PSS)9-modified electrodes to 
test the ability of the polyelectrolyte thin films to allow for adhesion and formation of 
confluent PD-MSCs layers.  
The polyelectrolyte substrates induced normal cell anchorage, with the cells attaching 
easily and exhibiting fast proliferation. When seeded at high density (5x105 cells/cm2), 
PD-MSCs formed confluent monolayers within 4 hours. The viability and phenotypical 
stability of the PD-MSC sheets grown on the PAH/PSS substrates were determined by 
live-dead staining and FACS analysis, respectively.  
Live-dead staining using calcein and ethidium homodimer showed that PD-MSCs in the 
confluent monolayers remained viable to a similar extent (95%) as cells grown in 
parallel under standard culture conditions on the TCPS plates (95%) [Figure 43]. 
Phenotypical characterization according the minimal criteria for determining of human 
MSCs stated by international society for cell transplantation (ISCT) indicated no 
significant changes in surface marker expression for the confluent PD-MSCs cultured on 
the PAH/PSS substrates [164]. Indeed, the cells were positive for HLA-ABC, CD73, 
CD90, and CD105 but negative for HLA-DR, CD14, CD34, and CD45 cell surface 
markers [Figure 44].  
 
  
 
Figure 43: Viability of stem cell sheets before peeling. (A) Cell sheet generated from 
placental MSCs on the experimental (PAH/PSS)9 coating; (B) Control cell sheet from 
placental MSCs grown on tissue culture polystyrene (TCPS). 
B A 
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Figure 44: Phenotypic profile of engineered stem cell sheets before peeling. Flow 
cytometrical analysis (FACS) revealed that phenotypic profile of undifferentiated stem cell 
sheets fulfil the minimal criteria for defining multipotent mesenchymal stromal cells as 
stated by the international society for cellular therapy (ISCT). Green lines denote 
unstained negative control cells.  
6.4. Plasticity of PD-MSC sheets grown on (PAH/PSS) substrates 
 
Medium-induced mesodermal differentiation of PD-MSC sheets 
PD-MSCs cultured as dense cell monolayers were further tested to determine whether 
they retained their potential to differentiate in vitro towards the mesodermal lineage. 
Adipogenic, chondrogenic, and osteogenic differentiation were determined using 
specific biochemical and immunocytochemical staining [Figure 45].  
Because typical mesodermal differentiation of MSCs takes three weeks, a stable 
adhesion of the cultured monolayers within this period was desired. PD-MSC 
monolayers remained stably attached to the (PAH/PSS)9 coated ITO surfaces for the 
whole period of culture in control as well as in osteogenic, and chondrogenic 
differentiation conditions. Contrastingly, the PD-MSC monolayers upon adipogenic 
differentiation (21 days) starting to detach from the PEM substrates and rolled up 
[Figure 45 B]. PD-MSCs could be successfully differentiated towards mesodermal 
lineage. Deposition of big amount of lipid droplets, expression of alkaline phosphatase 
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as well as expression of collagen type II were determined for the cell sheets induced in 
adipogenic, osteogenic, or chondrogenic differentiation media respectively [Figure 45 
B, D and F]. No sign of differentiation was observed for control, non-induced, PD-MSC 
monolayers [Figure 45 A, C and E]. 
 
 
 
Figure 45: Differentiation towards mesodermal lineage of PD-MSC monolayers cultured on 
(PAH/PSS)9 coated ITO substrates. Control stem cell sheets cultured in standard 
conditions without induction do not show any sign of differentiation (A,C, and E). 
Adipogenic differentiation as demonstrated by Oil Red O staining of lipid droplets (B), 
Osteogenic differentiation as demonstrated by Alizarin Red S-staining of calcification (D), 
Chondrogenic differentiation as demonstrated by immunocytochemical Collagen Type II 
and DAPI staining (F).   
 
Osteogenic differentiation of PD-MSC sheets by indirect cell contact 
Instructed mesodermal plasticity has been additionally demonstrated by co-culture of 
PD-MSC sheets in indirect contact with human osteoblasts. Osteogenic differentiation 
was performed using standard co-culture system for organotypic cultures and 
determined by colorimetric analysis of alkaline phosphatase production and by analysis 
of collagen type I expression using real-time PCR.  
A C E 
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Results obtained by colorimetrical staining [Figure 46], as well as by real-time PCR 
[Figure 47] show clear difference in expression of alkaline phosphatase between 
samples in induced conditions comparable with control conditions (co-culture of PD-
MSC with PD-MSC stimulated by OsteoDiff) as well as negative control conditions (co-
culture of PD-MSC with PD-MSC without additional stimulation) 
 
 
 
Figure 46: Differentiation of PD-MSC sheets towards osteogenesis by co-culture. Alkaline 
phosphatase (ALP) expression in control conditions (A), and in induced condition (B) as 
determined by colorimetrical analysis. 
 
 
Figure 47: Differentiation of PD-MSC sheets towards osteogenesis by co-culture as 
determined by expression of human collagen type I using real-time PCR. 
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6.5. Harvesting of PD-MSCs sheets 
 
Electrochemical trigger 
Samples with confluent PD-MSC monolayers grown on (PAH/PSS)9 coated electrodes 
were subjected to an electrochemical trigger to induce cell sheet detachment. While 
(PAH/PSS)9 thin films were shown to be stable for at least 30 minutes under the same 
electrochemical conditions, the PD-MSC sheets completely detached from the substrate 
within 10 to 20 minutes when subjected to a current density of 30 µA/cm² [Figure 
48].  
 
   
 
Figure 48: Peeling of placenta derived mesenchymal stem cell (PD-MSC) sheets from 
conductive substrates upon electrochemical polarization. PD-MSCs were grown to 
confluence on ITO substrates coated with a (PAH/PSS)9 thin film (A) and subsequently 
subjected to a current density of 30 µA/cm2. After 5 minutes of electrochemical treatment 
(B), the confluent cells remained attached to the substrate, while detachment of the whole, 
intact cell sheet was observed after 15 minutes (C).  
 
The PD-MSCs sheets were released from the substrate with intact cell-cell connections, 
and a fast adhesion was observed upon transfer to a new substrate, indicating the 
presence of extracellular matrix proteins under the harvested cell sheets. 
 
Bulk pH decrease 
The effect of a decrease in environmental pH on the adhesion of the confluent PD-MSCs 
was further assessed. PD-MSC sheets grown at physiological pH (7.4) on (PAH/PSS)9-
A B C 
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coated ITO electrodes were exposed to cell culture media buffered at pH values ranging 
from 7.4 to 4.0.  
The results demonstrated that cell attachment remained unchanged when the media 
was buffered above pH 5.0. However, when the pH value was reduced to 4.0, cells 
readily detached within 2-3 minutes as continuous, intact cell sheets [Figure 49]. The 
recovered cell sheets spontaneously attached when transferred on new dishes. 
 
 
 
Figure 49: Detachment of the PD-MSC sheets upon lowering of the bulk pH. Monolayer of 
PD-MSCs grown to confluence on ITO substrates coated with a (PAH/PSS)9 thin films at 
physiological pH = 7.4 (A). Stable attachment of PD-MSC sheet at pH=5 (B). Detachment of 
intact PD-MSC sheet after 2-3 minutes deposition of culture medium at pH=4     
6.6. Characterization of recovered PD-MSC sheets 
 
Viability 
The survival and functionality of PD-MSCs after release by electrochemistry and 
lowering of pH was tested immediately after the detachment by live-dead staining. As 
depicted, the live-dead staining performed within 2 hours after detachment of PD-MSC 
sheets, demonstrated that the cell survival was not significantly compromised [Figure 
50]. Furthermore, the results confirmed that PD-MSC sheets, harvested upon 
electrochemical trigger or reduction of the bulk pH (data not shown), retained their 
potential for adhesion and growth on novel TCPS substrates [Figure 51 A].  
Normally cell sheets manually transferred after electrochemical detachment started to 
adhere to fresh TCPS substrate within approximately 48 hours. Within next 7 days the 
first signs of cell sheet growth appeared [Figure 51 B].  
A B C 
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Figure 50: Viability of stem cell sheets after peeling. Viability of the cell sheets peeled by 
electrochemical stimuli (A), and decrease of bulk pH (B) as demonstrated by Live-Dead 
staining with calcein (green) specific for live cells and ethidium homodimer [220] specific 
for dead cells. 
 
    
 
Figure 51: Viability and adhesion capacity of transferred stem cell sheets. Viability of 
electrochemically peeled PD-MSC sheet (A) and their attachment to the TCPS surface after 
7 days of culture (B) as demonstrated by Live-Dead staining with calcein (green) specific 
for live cells and ethidium homodimer [220] specific for dead cells. 
 
Differentiation towards mesoderm induced by medium 
Differentiation of recovered PD-MSC sheets towards adipogenic and osteogenic lineages 
in vitro could be successfully shown by Oil Red O and Alizarin Red S staining, 
respectively [Figure 52]. The efficiency of this differentiation was comparable with the 
A B A 
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results obtained after mesodermal differentiation of confluent cell layers grown on 
(PAH/PSS)9 substrates deposited on ITO coated glass electrodes described above. 
Chondrogenic differentiation was not detachable. 
 
 
Figure 52: Mesodermal plasticity of stem cell sheets after peeling as demonstrated by 
appropriated biochemical stainings. Osteogenic differentiation as demonstrated by 
Alizarin Red S-staining of calcification after electrochemically mediated peeling (A) and 
colorimetric staining of alkaline phosphatase after pH mediated peeling (C). Adipogenic 
differentiation as demonstrated by Oil Red O-staining of lipid droplets after 
electrochemically mediated peeling (B) and after pH mediated peeling (D).    
 
Osteogenic differentiation of PD-MSC sheets by direct cell contact  
Finally, I demonstrated that recovered PD-MSC sheets retain potential to be 
differentiated towards osteogenic lineage by co-culture in direct cell-cell contact with 
human osteoblasts [Figure 53]. The ranges of collagen I expression by negative 
control, co-culture control and co-culture differentiation conditions were significantly 
different. The efficiency of this differentiation was comparable with the results obtained 
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after co-culture of PD-MSC sheets with human osteoblasts in the absence of cell-cell 
contact. 
 
Figure 53: Differentiation of recovered PD-MSC sheets towards osteogenesis by co-culture 
as determined by expression of human collagen type I using real-time PCR.   
6.7. Relevance (PAH/PSS) substrates for stem cell sheet engineering  
In the present study, a new platform for the growth and subsequent harvesting of stem 
cell sheets was explored. Robust (PAH/PSS) thin films were used as substrate for PD-
MSCs, and viable stem cell sheets were effectively released from the polyelectrolyte 
substrates through a local, electrochemically-induced pH lowering or a global pH 
decrease of the bulk solution. (PAH/PSS) multilayers promoted the formation of 
confluent PD-MSC monolayers while preserving the viability and differentiation potency 
of the adult stem cells. The stem cell sheets harvested upon electrochemical trigger or 
reduction of the bulk pH were able to adhere onto new TCPS surfaces, were viable, and 
could be successfully differentiated towards adipogenic and osteogenic lineages. In a 
previous work, native multilayers of poly-(L-lysine) and hyaluronic acid (PLL/HA) were 
shown to be poorly adhesive for PD-MSCs, despite efficient functionalization by 
adsorbed fibronectin, while highly cross-linked, stiffer (PLL/HA) multilayers were 
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proved suitable substrates for MSC adhesion and proliferation. [221] PLL and HA are 
weak polyelectrolytes which form relatively soft and highly hydrated coatings. 
Contrastingly, (PAH/PSS) assemblies present a dense, stratified structure resulting in 
much stiffer films, and a variety of other cell types, including stem cells, have been 
successfully cultured on (PAH/PSS) substrates [207, 222-232]. In this work, 
(PAH/PSS)9 films allowed for the adhesion and growth to confluence of PD-MSCs 
without affecting  
the stem cell‟s viability, phenotype and multipotency, further substantiating the 
promising properties of (PAH/PSS) coatings for biomedical applications. Placental MSC 
sheets grown on (PAH/PSS)9 films completely detached within 10 to 20 minutes when 
subjected to a current density of 30 µA/cm2. Parallel, EcAFM experiments showed that 
the same electrochemical stimuli applied for 30 minutes was not sufficient to induce the 
coating dissolution, in good agreement with a previous report which showed a delayed, 
slow dissolution detectable after only 120 minutes at similar electrochemical conditions 
[233]. According to previous studies, the electrochemically-induced degradation of 
polyelectrolyte multilayers relies on the neutralization of the electrostatic interactions 
within the assemblies, as a consequence of water electrolysis which results in a 
continuous production of protons at the electrode surface as it is depicted on the 
schema: 
2H2O → O2 + 4 H+ + 4e- (E0 = 1.23 vs. NHE) 
Due to the low pKa value of PSS sulfonate groups (pKa ~1), the destabilization of 
(PAH/PSS) assemblies requires a very high concentration of protons, hence its delayed, 
slow dissolution. The dissolution of polyelectrolyte assemblies has been previously 
shown to be dependent on the intensity of the electrochemical stimuli applied, with 
higher potentials/currents yielding faster dissolution. The stability of (PAH/PSS)9 thin 
films was thus assessed under a higher current density. The integrity of the thin films 
was maintained for at least 30 minutes under the increased electrochemical stimulus. 
These results clearly demonstrate that the cell sheet detachment observed in this study 
did not rely on the dissolution of the cell‟s underlying substrate, in contrast to the 
former electrochemical approaches for cell sheet engineering. 
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While the applied electrochemical trigger was insufficient to induce the degradation of 
the (PAH/PSS) thin films, it has been previously evidenced that the pH lowering 
induced by the electrochemical reaction can extend above the film. Indeed, weak 
(PLL/HA) assemblies, more sensitive, deposited on the top of a (PAH/PSS) thin film 
were shown to dissolve readily upon electrochemical trigger [233]. It can thus be 
assumed that in this work the pH at the film/cells interface decreased upon 
electrochemical stimuli. The interface between the cells and the substrate consists of a 
rich and complex protein layer, and a change in pH may greatly affect the protein-
protein or protein-substrate interactions, and the individual protein conformations. 
Such perturbations in the protein layer on which the cells are adhering may induce the 
detachment of the cells. To verify this hypothesis, the effect on cell adhesion of a 
decrease in the bulk pH was evaluated. An environmental pH of 4.0 was found to induce 
a rapid detachment of the cell sheets, while pH comprised between 7.4 and 5.0 had no 
effect on the cells attachment on (PAH/PSS) substrates.  
The integrity of (PAH/PSS)9 films immersed in a solution at pH 4.0 was confirmed by 
AFM measurements, excluding a substrate dissolution as a cause of cell detachment. 
These results confirmed that the cell sheet detachment was induced by a lowering of the 
pH, either local (electrochemically-induced) or global. The electrochemically-induced 
pH lowering leaded to a slower cell sheet detachment compared to a direct change of the 
cover medium pH, a delay most probably due to the  time necessary for the production 
of a sufficient amount of protons to reach a pH of ~4 above the polyelectrolyte substrate. 
It is well known that local pH changes in a cell micro-environment can significantly 
affect final population density, reversal of contact inhibition of growth, or efficiency of 
cell fusion in vitro [234]. For this reason, cell surrounding pH must be kept within 
relatively narrow limits for the maintenance and stable growth of most cell cultures. As 
previously reported by Taylor et al., the elevation of the environmental pH can lead to 
acceleration of cell movements and cause cytoplasm contraction, while the lowering of 
pH can retard and stop cell activity, causing apparent gelation of the protoplasm [235]. 
Earlier Cecarrini and Eagle already demonstrated that the growth rate as well as the 
maximum population doubling of whether normal, cancer, or virus-transformed cell 
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types were markedly pH dependent. The optimal pH ranges varied from 6.9 for the 
rabbit lens cells, to 7.8 for human fibroblast [236].  
The effect of electrochemically-induced pH lowering on the viability of cells grown 
directly on an electrode has been studied by Gabi et al. Results showed that current 
densities up to 38 µA/cm2 did not significantly affect cell viability, while 58 µA/cm2 
induced transient pore formation in the cell membrane, and an electrochemical trigger 
≥ 76 µA/cm2 induced cell death. They also showed that a pH ≤ 2 induced cell death 
[237]. 
6.8. Achievements of the sixth part 
In the third part of my thesis I evaluated potential usability of (PAH/PSS) 
polyelectrolyte multilayer substrates for engineering, differentiation, and controllable, 
electrochemically mediated detachment of the PD-MSC sheets. For this I assessed the 
effect of both local and global pH reduction on the viability and differentiation potential 
of the PD-MSC sheets. Live-Dead staining as well as differentiation assays of the 
harvested MSC sheets demonstrated that the pH decrease inducing the cell sheet 
detachment had no adverse effects on the cells. Beside their good properties for cell 
culture, the thin (PAH/PSS) films might also shield the cells from reactive products 
produced by the electrochemical reactions at the electrode surface. Indeed, beside 
reactive oxygen produced upon water electrolysis, the electrochemical stimuli may also 
induce the formation of amine reactive hypochloric acid [237]. These highly reactive 
moieties could have cytotoxic effects on cells attached directly on the electrode. 
However, these products cannot diffuse through a (PAH/PSS) film but will react and be 
neutralized at the electrode/polyelectrolyte interface.  
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CONCLUSIONS  
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Despite its remarkable progress, regenerative medicine is still faced with critical 
challenges such as correct tissue integration and survival as well as prevention of 
rejection and inflammations. Today‟s regenerative medicine strategies rely on the use of 
cells, biomaterials, growth factors and cell culture systems to form tissue replacements 
ex vivo or stimulate tissue regeneration in situ. New research efforts are currently 
directed towards the formation of well-tolerated, viable, and functionally-integrated 
tissue structures.  
My project focuses on the formation of scaffold-free stem cell assemblies. In context of 
the project a highly-reproducible, straightforward method for the isolation of 
multipotent MSCs from human term placentas was developed and an approach based 
on conductive polyelectrolyte multilayer (PEM) coatings for the electrochemically-
mediated harvest of placental mesenchymal stem cell sheets was established. These 
coatings turned out to be suitable substrates for such human end-differentiated cells as 
chondrocytes, osteoblasts, and smooth muscle cells. Moreover they permitted the 
formation of cell sheets using such human stem cell sources as placenta-derived MSCs, 
adipose tissue-derived MSCs, and late outgrowth endothelial progenitor cells.  
Obtained results demonstrated that the mechanical behaviour of the PEM coating 
specifically influenced the efficiency of cell adhesion. Further, cell sheet peeling can be 
achieved through an electrochemically-induced local pH decrease.  
As AFM results do not show any sign of the coating disintegration, this suggests that the 
recovered cell monolayers are free of polymer, which is desirable for potential clinical 
applications. Furthermore, the integrity of the PEM substrate after cell sheet 
detachment is promising when envisioning multiple uses of the same substrate.   
The cell sheets detached as a result of electrochemical stimulus, even in absence of 
surface dissolution. This effect might be due to electrochemically-induced reduction of 
the local pH. Since cell sheet release could be reproduced by low environmental pH, the 
electrochemically-induced release could be attributed to a local drop in pH.  
I propose that, reasonably-priced PEM-based systems might be used for the generation 
of cell layers with site specifically released or modified areas or could be explored to 
form cell sheets that consist of different cellular components that can be patterned in  
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2D. Specific deposition of endothelial cells might allow for the construction of vascular 
trees spanning the 3D constructs, which were formed by multiple cell sheets. Such 
biomaterial-free tissue replacements would address at least two of the tissue 
engineering challenges (neovascularization and correct tissue integration) therefore 
improving the integration and reducing the adverse immunological properties of such 
tissue-like structures.  
Further studies are required to evaluate the properties of PD-MSCs regarding their full 
differentiation capacity in vitro and in vivo. Aside from evaluating their utility in future 
cell replacement therapies and tissue engineering, it is important to assess PD-MSCs 
potential for exploitation in transplantation medicine. It would be most favourable if 
PD-MSCs could exert immunosuppressive effects and/or secrete proangiogenic and 
antiapoptotic cytokines for the promotion of tissue healing. Furthermore, it will be 
important to evaluate the potential of (PAH/PSS) coatings as a carrier-substrate for the 
eventual triggering of growth factors, hormones, or other agents that stimulate stem cell 
differentiation. 
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8.2. ABBREVIATIONS 
 
Cell culture techniques 
MSC – Mesenchymal Stem Cells 
PD-MSC – Placenta-derived Mesenchymal Stem Cells 
AT-MSC – Adipose Tissue-derived Mesenchymal Stem Cells 
HUVEC – Human Umbilical Vein Endothelial Cells 
NHDF – Normal Human Dermal Fibroblasts 
OEC – Late Outgrowth Endothelial Cells 
TCPS – Tissue Culture Polystyrene 
HCH – Human Chondrocytes 
HOB – Human Osteoblasts 
HF – Human Fibroblasts 
C2C12 – Mouse Muscle Cell Line (Mus Musculus) 
FN – Human Recombinant Fibronectin 
ALP – Alkaline Phosphatase 
BCIP/NBT – (5-Bromo-4cloro-3-indolyl phosphate/Nitro Blue Tetrazolium) 
 
Polymers 
PEM – Polyelectrolyte Multilayer  
PLL – Poly-L-Lysine Hydrobromide 
HA – Hyaluronic Acid Sodium Salt 
PAH – Poly(allylalanine)Hydrochloride 
PSS – Polystyrene Sulfonate 
 
Crosslinkers and buffers 
HEPES - (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
HEPES-2 - (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) with 1.8 Mm NaCl 
EDC - 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimid 
NHS - N-hydroxysulfosuccinimide 
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Analytical techniques 
FACS – Fluorescent Activated Cell Sorting 
FITC / TRITC – Fluorescein Isothiocyanate / Tetramethylrhodamine Isothiocyanate 
PE – Phycoerythrin 
APC – Allophycocyanin 
PCR – Polymerase Chain Reaction 
AFM – Atomic Force Microscopy 
OWLS – Optical Wave Length Spectrometry 
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